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This report presents the results of a study that investigated the misuse and diversion 
of prescription-only-medication and over-the-counter-medication (POM/OTC) among 
people who use illegal drugs. The study was conducted by a team of researchers from 
the University of South Wales in collaboration with Dr Rhian Hills from the Substance 
Misuse Policy Branch within the Welsh Government. The research was undertaken 
across Wales and was based on qualitative interviews with a sample of people who 
had lived experience of prescription drug misuse, and also included an online 
questionnaire survey completed by professionals working within the field of substance 
misuse.   
 
The main aim of the study was to identify the causes, patterns and consequences of 
POM/OTC misuse and diversion among people with a history of illegal drug use.   
 
For the purpose of this document in relation to POM/OTC use, we have used the term 
nonmedical prescription drug use and its associated acronym (NMPDU) to refer to the 
misuse of prescription-only medication. Definitions of key terms are presented below 
and followed by information about the prevalence of NMPDU among both the general 
and drug-using population.   
 
This is then followed by a brief overview of the potential harms that are associated 
with this behaviour and the responses that are often used to try to counteract it.  The 
study ends with brief chapter summaries to provide readers with an overview of the 
report structure and content.  
  
Background 
Nonmedical prescription drug use (NMPDU) typically involves the consumption of a 
prescription-only medication without a doctor’s prescription, or in a way not in 
accordance with prescription guidelines (Bennett, Holloway, & May, 2018; Cicero & 
Ellis, 2017; Hulme, Bright, & Nielsen, 2018). This could include the consumption of a 
medication at a higher or more frequent dose, prolonged duration of use, altering of 
administration routes, and/or concurrent or consecutive use of other medications or 




Medications with demonstrated NMPDU includes prescription opioids (e.g. 
methadone, buprenorphine, oxycodone, tramadol) (Allen & Harocopos, 2016; 
Dertadian, Iversen, Dixon, Sotiropoulos, & Maher, 2017; Inciardi, Surratt, Cicero, & 
Beard, 2009), benzodiazepines (e.g. alprazolam, diazepam), (Mateu-Gelabert et al., 
2017; Weaver, 2015) and prescription stimulants (e.g. amphetamine, 
methylphenidate) (McCabe, Veliz, Wilens, & Schulenberg, 2017; Weyandt et al., 
2016). Motivations for NMPDU often relate to self-medication (Bennett & Holloway, 
2017; Rigg & Ibanez, 2010), to prolong the intensity and duration of other substances 
(Jones, Mogali, & Comer, 2012; Silva, Kecojevic, & Lankenau, 2013) or to alleviate 
the severity of withdrawal symptoms or adverse effects of other substances (Chen et 
al., 2011; Mateu-Gelabert et al., 2017).  
 
Prevalence of NMPDU among the general population 
There is some evidence to suggest that NMPDU now exceeds the use of most illicit 
drugs in some countries (UNODC, 2019). For example, among the general population 
in the United States, the nonmedical use of prescription painkillers and tranquillisers 
are behind only the illicit use of cannabis, with 3.3 and 2.0 million people aged 12 or 
older currently using them non-medically (SAMHSA, 2017). In England and Wales, 
6.4% of adults aged 16 to 59 (approximately 2.2 million people) reported that they had 
used prescription painkillers that had not been prescribed to them in the last year 
(Home Office, 2019).   
 
These trends are a concern due to the unintended health and social consequences 
that are often associated with the practice, including rapid tolerance, dependence and 
fatal and non-fatal overdose, particularly when used in combination with other 
substances (Hulme et al., 2018; Lyndon et al., 2017; Macleod et al., 2019; Mateu-
Gelabert et al., 2017; Schepis, 2018). Indeed, mortality rates linked to prescription 
medication used either alone or as a component of poly-drug use have increased over 
the last decade in Australia, Canada, the United States and the United Kingdom 
(Bennett et al., 2018; Hulme et al., 2018). In England and Wales, noticeable increases 
in drug-related deaths have occurred in relation to prescription opioids, 
benzodiazepines, antidepressants and gabapentinoids (ONS, 2019). Given the 
potential health and social harms associated with the practice, NMPDU is now an 
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important public health issue worldwide (ACMD, 2016; EMCDDA, 2018; UNODC, 
2019). 
 
Prevalence of NMPDU among people who use opioids 
NMPDU is particularly widespread among people who use illicit opioids (Jones et al., 
2012; Lyndon et al., 2017). For example, data on those in specialised drug treatment 
in Europe found that 12% of entrants for opioid-related problems reported 
benzodiazepines as a secondary problem drug (EMCDDA, 2018)1. Higher figures for 
the concomitant use of benzodiazepines among individuals in receipt of methadone 
have been found elsewhere, ranging from 39.8% in the United States (Chen et al. 
(2011) to 70% in Germany (Specka, Bonnet, Heilmann, Schifano, & Scherbaum, 
2011). Similarly high prevalence rates have been found among individuals in receipt 
of buprenorphine (46%) (Lavie, Fatséas, Denis, & Auriacombe, 2009), whilst Darke 
and colleagues have consistently identified the nonmedical use of benzodiazepines 
alongside heroin (Darke & Hall, 1995; Darke et al., 2010; Ross & Darke, 2000); in one 
study, 2 out of 3 people who inject heroin reported nonmedical benzodiazepine use 
within the last year (Ross & Darke, 2000). 
 
Harms and responses to NMPDU 
NMPDU is particularly problematic among this population as medications such as 
benzodiazepines and gabapentinoids can potentiate the harmful effects of opioids - 
including respiratory depression - thereby increasing the likelihood and lethality of 
overdose (Jones et al., 2012; Lyndon et al., 2017; Macleod et al., 2019). In many 
European countries, benzodiazepines are commonly implicated in overdose deaths 
attributed to the use of opioids (EMCDDA, 2019), whilst between 2004 and 2015 
opioids were involved in 79% of gabapentinoid deaths in England and Wales (Lyndon 
et al., 2017).  
 
The harms associated with NMPDU are one influence on current prescription 
medication regulations worldwide (Harris & Rhodes, 2013; Mateu-Gelabert et al., 
2017; McNeil et al., 2015). The daily consumption of opioid substitution therapy (OST) 
                                                     
1 Figure based on treatment data from 22 EU countries (Austria, Belgium, Cyprus, Czech Republic, Denmark, 
Finland, France, Greece, Ireland, Italy, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, 
Slovenia, Spain, Sweden, Turkey, United Kingdom). Figure is considered an underestimate as problems with 
secondary drugs are not always recorded or reported (EMCDDA, 2018).  
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medications (methadone, Subutex, Espranor) under the supervision of a pharmacist 
or healthcare professional remains the recommended best practice for reducing the 
nonmedical use of these medications (Strang, Hall, Hickman, & Bird, 2010) 2 . 
Prescription Drug Monitoring Programs (PDMPs) have also been introduced in the 
United States to collect, analyse and monitor practitioner and patient habits in order to 
detect the inappropriate or illegal prescribing of medications (Pardo, 2017). In England 
and Wales, the Advisory Council on the Misuse of Drugs (ACMD) (2016) has 
recommended that medical practices establish data collection systems to identify 
patients who are, or are suspected of being, dependent on prescription drugs, and 
there have been recent calls for doctors to avoid co-prescribing benzodiazepines to 
opioid dependent patients due to the increased risk of overdose mortality (Macleod et 
al., 2019).  
 
Report overview 
In this first chapter (1.0) we have provided general information about the aims of the 
study as well as background information to put the research into context.   
 
In the second chapter that follows (2.0), we present a rapid evidence assessment of 
the literature on prescription drug misuse to show the current state of knowledge on 
the topic.  
 
Chapter 3.0 provides information about the design of the study, its strategy and the 
methods of data collection that were used to gather data.  This chapter also provides 
an overview of the methods of analysis as well information about the characteristics 
of the samples recruited.  
 
Chapter 4.0 is the first of the results chapters, focusing on findings from the interviews 
undertaken with people with lived experience of NMPDU.  
 
                                                     
2 The need for supervised consumption can be relaxed, however, should individuals in receipt of OST show 
evidence of clinical progress, including compliance with treatment and recovery care plans, changes in drug-
taking behaviours (e.g. cessation of injecting) and abstinence (Clinical Guidelines on Drug Misuse and 
Dependence Update 2017 Independent Expert Working Group, 2017).  
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This is followed by the second results chapter (chapter 5.0 which presents findings 
from the online questionnaire survey of professionals with experience of 
commissioning, managing or delivering OST in Wales.  
 
Chapter 6.0 is the discussion chapter where we reflect on both sets of findings in light 
of the literature reviewed in Chapter 2.0.   
 
The report ends with a concluding chapter (7.0) in which we summarise the key points 
and make a series of recommendations for policy (Chapter 8.0), practice and future 
research.  
 





2.0 Literature review 
 
In this chapter we present findings from a rapid evidence review of the literature on 
NMPDU. Our aim is to provide readers with a summary of the current state of 
knowledge on the topic of NMPDU.  The chapter begins with details of the systematic 
review methods used to identify relevant studies and then moves on to discuss the 
findings, which have been grouped in key themes.  
 
Methods 
The rapid evidence review was undertaken to identify publications relating to the 
misuse of prescription medication. To this end, searches were undertaken of one 
bibliographic database, ASSIA. The search term used for the database searches was: 
 
   ti(Prescription only medication) AND ti(misuse OR abuse OR diver*) 
 
To be eligible for selection, the study had to present the results of study that 
maintained: (1) a focus on a prescribed medication, and (2) a focus on the misuse of 
this prescribed medication in some way.  
 
The initial search of the data produced a total of 3036 studies. Based on the large 
quantity of this search, it was decided that the initial screening would focus on the 50 
most relevant studies according to titles, which would then be supplemented by 
searches of Google Scholar using the same search algorithm. The titles and abstracts 
of these studies were then reviewed and the full publications obtained when they 
appeared to match our research interest. The papers from the database search and 
the references from the published papers were then read and those that met our 
selection criteria were included in the review. 
 
After excluding five studies (due to them not being accessible) from the fifty most 
relevant studies, 45 studies were screened based on their title and abstract to 
determine whether they fit the inclusion criteria. At this point, 23 studies were excluded 
due to their relevance or based on them missing a part of the inclusion criteria. From 
this, the remaining publications were then examined more thoroughly to determine 
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whether they were indeed suitable to include. Another three studies were then 
excluded due to their relevance, meaning that 19 studies were deemed eligible of 
meeting the criteria. These searches were supplemented by four more relevant studies 
found during google scholar searches. Below is a Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) flow chart (Fig. 1.) detailing the 
search process.  
 






























Records after duplicates removed 
(n=3035) 
Records excluded (n=3011) 
No access (n=5) 
Not relevant (n=23) 
Full text articles obtained 
(n=22) 
Records excluded (n=0) 
Full text articles assessed for eligibility 
(n=22) 
Full text articles included in the review 
(n=19) 
Excluded studies 
Not in English language (n=0) 




Thematic coding and summary of key points 
The main themes to emerge from the searches related to the following two themes: 
(1) Motivations and reasons for POM misuse, and (2) sources and methods of POM 
for misuse. These themes, along with their relevant subthemes, will be discussed in 
turn below.  
 
Motivations/reasons for misuse 
 
Recreational motives 
Recreational motives were found to be a common motive for NMPDU. In all studies 
suggesting this, it was found that NMPDU frequently occurred in attempts to ‘get high’, 
often as a way to take away any boredom that the individual may have felt prior (Alam 
& Barker, 2014; Carretta et al., 2018; Desantis et al., 2008; Green, 2017; Tete et al., 
2005; Quintero, 2009; White et al, 2006). Most papers discussing recreational NMPDU 
involved student samples, however (Desantis et al., 2008). Quintero’s (2009) study on 
recreational NMPDU among college students for example, suggested that prescription 
medications were routinely used to experience pleasure and facilitate socio-
recreational activities.  
 
Self medication 
A small body of research has also acknowledged how NMPDU is used to self-
medicate and alleviate legitimate medical concerns. (Harris & Rhodes, 2013; Koester, 
Anderson, & Hoffer, 1999; Mateu-Gelabert et al., 2017; Richert & Johnson, 2015). Foe 
example, Harris and Rhodes (2013) detailed how the strategic stockpiling of doses of 
methadone was used to safeguard against withdrawal. Diverted methadone thus 
functioned as an ‘indigenous harm reduction strategy’ that enabled participants to 
manage their drug use, avoid withdrawal and cement social relationships with other 
drug users (more information in relation to self medication can be found on page 49).  
 
Similarly, Mateu-Gelabert et al. (2017) noted how the risks associated with 
concomitant benzodiazepine use were often rationalised and offset by the more 
immediate priorities experienced by people who use drugs on a daily basis. This 
included enhancing the effects of one’s high or managing withdrawal in situations 
where opioids were unobtainable. Finally, Richert and Johnson (2015) examined the 
motives for non-prescribed methadone and buprenorphine use among people with 
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opioid dependence. It was found that self-treatment with non-prescribed OST 
medications began as a result of barriers to legitimate OST treatment, including 
difficulties in accessing and remaining in treatment and a reluctance to engage in OST 
due to fear of stigmatisation or disciplinary action (for example, involuntary discharge). 
The findings led the authors to recommend the expansion of OST provision to reduce 
the illicit demand for these substances. 
 
Existing substance misuse or psychiatric issues: 
Among the papers looking at populations likely to engage in NMPDU, histories of 
substance misuse or psychiatric disorders were often noted (Allen et al., 2014; 
Carretta et al., 2018). Links between the two were often found in relation to opioid-
based prescriptions. For example, Weigel et al (2007) suggested that there was a 
strong link between psychiatric conditions (including major depressive disorder) 
suicide attempts and childhood sexual abuse and NMPDU. Further, Bastiaens et al 
(2016) reported that 26% of their sample of opiate addicted patients reported illegally 
obtaining, overusing, or malingering to obtain gabapentin. 
 
Attention/grades: 
One of the main motivations given for NMPDU was to enhance attention and 
concentration. This was particularly true for those within academically stressful 
situations (Desantis et al., 2008). Teter et al (2005) suggested that students used 
prescription drugs “to help concentrate”; which accounted for the majority of motives 
given by their sample. Further, Desantis et al (2008) found that 34% of students 
reported the NMPDU of Attention deficit hyperactivity disorder (ADHD) stimulants. 
Most participants reported using ADHD stimulants assisted in periods of high 
academic stress, and found them to reduce fatigue while increasing reading 
comprehension, interest, cognition and memory.  
 
Sources of POM for misuse 
 
Inappropriate prescribing practices  
Inappropriate prescription practices were found to be one of the leading source of 
medications for NMPDU (Alam & Barker, 2014; Allen et al., 2014; Green, 2017; Ratycz 
et al., 2018; Schmidt et al., 2015; Worley, 2014). Mack et al (2015) found that 30% of 
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opioid prescriptions overlapped with other opioid prescriptions. Within the sample, 
patients obtained an average of 6.3 opioid prescriptions, even with 40% of this sample 
having at least one indicator of potential misuse. It was also evident that there was a 
lack of knowledge by both healthcare professionals and the general population in 
relation to prescription medication, including what is deemed appropriate prescribing 
practice and how to appropriately assess and manage patients (Green, 2017; Allen et 
al., 2014; Schmidt et al., 2015; Mayhew, 2010). 
 
Lack of care/monitoring: 
Similar to the above, studies suggested that there was a lack of monitoring and care 
within many healthcare settings for people engaged in NMPDU (Mayhew, 2010). 
Improvements in this area are suggested by almost all of the papers analysed (Alam 
and Barker, 2014; Carretta et al., 2018; Mack et al., 2015; Mayhew, 2010; Worley, 
2014; Weigel et al., 2007). As such, it was recommended that care and monitoring 
should be paired with an improvements in prescribing knowledge. This included 
pain/risk assessments and appropriate duty of care measures (i.e. substance misuse 
red flags, full attention to diagnoses, and personalised monitoring plans) (Alam & 
Barker, 2014; Weigel et al., 2007; Worley, 2014).   
 
Doctor shopping/forging prescriptions: 
Doctor shopping (requesting specific doctors who participants knew would be more 
willing to prescribe them medication ) and forging prescriptions was found to be a large 
problem within health care settings and a consistent source of medication for NMPDU 
(Mayhew, 2010; Schmidt et al., 2015; Weigel et al., 2007; Worley, 2014). Papers 
tended to focus on doctor shopping and forging from a healthcare perspective, and 
the ways in which practitioners could alter practice to prevent such use from occurring. 
They suggest that more care in prescribing practices and increased monitoring need 
to be utilised in order to reduce or prevent this issue (Mayhew, 2010; Schmidt et al., 
2015; Weigel et al., 2007; Worley, 2014). 
 
Peers/family: 
Finally, many studies cited peers and family members as a key source of medications 
for non-medical use (Desantis et al., 2008; White et al., 2006). Rhoades et al (2014) 
suggested that within the homeless youth population, one-quarter of the population 
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had obtained free prescription drugs from friends and families. Similarly, Harris and 
Rhodes (2013) noted that the sharing and giving of methadone to alleviate a peer’s 
withdrawal is a common practice among people who use drugs. The sharing of 
prescription medication system – which has been referred to as a ‘moral economy of 
sharing’ (Bourgois, 1998; Bourgois & Schonberg, 2009) – is often underpinned by an 
altruistic and emphatic bond between peers: peer groups are often willing to share and 
support any other person engaged in NMPDU, but there is an expectation that 
reciprocity occurs if the sharer was ever in future need (Bourgois & Schonberg, 2009; 
Harris & Rhodes, 2013). Similarly, Alam & Barker (2014) suggested that 30% of their 
sample who received a medication legitimately frequently diverted it to another person.  
 
Summary 
Understanding the use and motives for concomitant NMPDU is an important step in 
creating pragmatic harm reduction solutions. Yet, despite these studies producing 
several important findings, there is still more to be learned on this topic (Mateu-
Gelabert et al., 2017). Prior research has focused on the nonmedical use of individual 
medications such as methadone (Harris & Rhodes, 2013) and benzodiazepines 
(Mateu-Gelabert et al., 2017) alongside opioids, meaning the various functions and 
motives for the nonmedical use of other medications are less well understood. 
Additionally, much of the existing research on the NMPDU and its relationship with 
opioid use has been conducted in the United States (Koester et al., 1999; Mateu-
Gelabert et al., 2017; Rigg & Ibanez, 2010), a country where localised prescription 
regulations and controls have contributed to unique prescription drug use trends 
among its population (Bennett et al., 2018). Accordingly, there is a need to produce 
more general research on the motivations for NMPDU among people who use opioids 
in the UK, particularly in prison settings where it is considered a major concern (Bi-
Mohammed, Wright, Hearty, King, & Gavin, 2017). 
 
To conclude, this study aimed to investigate qualitatively the motivations for NMPDU, 
including its harm reduction and therapeutic potential, among people who use opioids 
in Wales, UK. Understanding the motivations has the potential to optimise treatment 
and service provision, including improving access to services and encouraging 






In this chapter we describe the methods that were used to conduct the research. We 
begin with an overview of the aims and objectives of the study as well as details of the 
funding arrangements and the timescales involved. The next section focuses on the 
research design and strategy that underpin the research. This is followed by a 
description of the choice of methods of data collection and details of how in practice 
the data was gathered and analysed.  
 
In the next paragraph, details of the ethical approval processes undertaken are 
presented along with a brief summary of how we adhered to the key ethical principles.  
The chapter ends with a section in which characteristics of the two samples are 
presented.  The overarching aim of the chapter is to provide readers with a clear 
appreciation of how the research was conducted, why the chosen approach was 
adopted and the type of people who participated.  
 
Aims and objectives 
The research was commissioned in early 2017 and funded by the Welsh Government 
(WG) with additional financial support from the University of South Wales3.  Initially, 
the brief was to conduct qualitative research on the misuse and diversion of opioid 
substitution treatment (OST), which had been flagged up in an Advisory Council for 
the Misuse of Drugs report on drug-related death and in the WG’s Substance Misuse 
Delivery Plan 2016-18 as an area for further investigation.  A few months later, WG 
issued a further amount of funding to extend the research to include the misuse of 
prescription-only and over-the-counter medicines, which were also highlighted within 
the 2016-18 Delivery plan.   
 
The original aims of the research were fairly broad. For clarity the research team, in 
collaboration with WG, narrowed the overarching aims down to the following key 
objectives: 
 
                                                     
3 A significant delay was experienced in starting the research due to the need to obtain NHS ethical approval for 
including NHS patients.  The process obtaining this approval took more than a year to negotiate.  This delay, 
coupled with the project manager’s five-month period of maternity leave, meant that the research did not get 
fully underway until well into 2018.  
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• To investigate motivations for POM/OTC misuse 
• To examine patterns of POM/OTC misuse 
• To consider the consequences of POM/OTC misuse 
• To investigate motivations for the diversion of POM (including OST) 
• To examine patterns of diversion of POM (including OST) 
• To consider the consequences of diverting POM (including OST) 
• To provide Welsh Government with a report summarising the research findings 
 
As stated in the introduction, it was agreed at an early point in the study period that 
the research would include two samples: (1) people with lived experience of POM/OTC 
misuse, and (2) people involved in the commissioning, managing or delivery of 
substance misuse services.  It was also agreed that the samples would differ in terms 
of the research focus.  For those with lived experience of POM/OTC misuse, the 
research would investigate the misuse of a range of prescription-only and over-the-
counter medications, including opioid substitute treatment (OST). However, for those 
working as professionals in the field, the research would focus on one particular kind 
of prescription-only medication, namely, OST.   
 
The need to focus the research in this way was driven largely by financial constraints. 
Funding for the project was limited and conducting, transcribing and analysing 
interview data is often costly. In consultation with WG, we therefore prioritised 
conducting interviews with people who had lived experience of the different kinds of 
drug misuse and opted for a cheaper, but nonetheless useful, online questionnaire 
survey to investigate the views and experiences of professionals working in the field.  
In an effort to maximise the response rate, we kept the survey as short as possible, 
which necessitated a focus on just one type of medication (OST) rather than the 
exploration of many types.  As a result, there is a slight imbalance in that we have 
more data (from two different perspectives) on the misuse and diversion of OST than 
on POM/OTC.  
 
Research design and strategy 
The study was based on a cross-sectional design in which participants were 
interviewed or surveyed at a point in time about their experience and understanding 
of issues relating to the misuse of POM/OTC/OST and the diversion of POM/OST.  
The strategy adopted was largely qualitative although some quantitative data were 
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also collected (e.g. demographic details, number of treatment episodes, drug use 
patterns, professional role, etc.). The focus on qualitative data collection enabled us 
to gather detailed information about our participants’ experience and understanding of 
the key issues (Bryman 2016).  
 
Research methods 
As noted above, the methods of data collection differed by sample.  Those with lived 
experience were interviewed about their experiences while those working in the field 




Semi-structured interviews with people with lived experience of the issues were 
conducted in statutory and third sector drug treatment organisations operating in five 
towns and cities across Wales, including two Welsh prisons. The use of semi-
structured interviews enabled the collection of in-depth data on personal experiences 
of NMPDU from the service users’ perspective (Bryman, 2016). 
 
Convenience sampling was used to recruit eligible participants. In practice, this 
involved a combination of methods including: advertising the research via bespoke 
posters and fliers within agency and prison settings; using key stakeholders working 
in the field to promote the research to eligible participants on our behalf; and members 
of the research team promoting the research verbally to potential interviewees in OST 
dispensing settings. Eligibility was based primarily on whether the person was 
currently (or previously) a user of illegal drugs and had recent experience of NMPDU. 
 
Interviews were conducted in rooms within the treatment facility or prison using a pre-
prepared interview schedule that posed questions about the participant’s drug use 
history and experiences of using prescription medications. The semi-structured nature 
of the interview allowed for the ordering of questions on the schedule to vary 
depending on the priority given to each topic by the participant (Barbour, 2007). Data 
collection concluded once the theoretical saturation of themes occurred, in other 
words, where instances of data emerged consistently and led to the conclusion that 





An online questionnaire survey was used to gather data from professionals with 
experience of commissioning, managing or delivery OST in Wales. As noted above, 
the decision to use an online questionnaire survey was made for financial reasons.  
While we would have preferred to investigate and discuss the issues in some depth 
with key stakeholders, we did not have sufficient funding to support the conduct, 
transcription and analysis of any more qualitative interviews.  We therefore opted to 
use questionnaires but ensured that we included a good range of open-ended 
questions that would generate qualitative data.   
 
A link to the survey was disseminated by email and through social media (i.e. Twitter) 
using our networks of contacts in the field.  The sampling approach was therefore a 
combination of convenience and snowballing methods. Eligibility was based primarily 
on whether the person was working in the field and had experience of either 
commissioning, managing or delivering OST in Wales.  
 
Ethical issues 
Ethical approval was obtained from the following three organisations:  
(1) The Faculty of Business and Society Research Ethics Committee at the University 
of South Wales,  
(2) Her Majesty’s Prisons and Probation Service (HMPPS), and  
(3) The NHS Research and Development Committees of participating Health Boards 
in Wales (following centralised NHS Research Ethics Committee (REC) approval).  
 
Participation in the research was voluntary and all participants were provided with 
details verbally and/or in writing about the nature and purpose of the research and 
what their participation would involve. Interviewees were advised that their responses 
would be kept confidential, unless they expressed an intent to harm themselves and/or 
someone else.  Survey respondents were informed that the survey was anonymous 
and that their responses could not be linked back to them.  Nevertheless, they were 
advised to avoid mentioning any names or identifying information in their questionnaire 




While all interviewees were asked to sign a consent form to indicate their agreement 
to participate, survey respondents were informed at the start of the survey that 
completing the survey implied that they had consented to take part. Interviewees were 
advised that they could stop the interview at any point and withdraw from the study at 
any point up until the point of starting the data analysis.  Survey respondents were 
advised that they could leave the survey at any point up until they had clicked FINISH 
at the end.  At this point, their survey responses would be submitted and, given the 
anonymous nature of the survey, it would no longer be possible to withdraw their data.  
 
Methods of analysis 
 
Interview study 
With the permission of participants, interviews were digitally recorded and 
subsequently transcribed securely by Avonlea Services Ltd.  Audio recordings were 
deleted once this process was completed. Written transcripts were printed out for each 
member of the research team and electronic versions were uploaded to NVivo version 
12 software to enable computerised data analysis. Initially, the hard copy transcripts 
were read independently by the four researchers, who highlighted and discussed 
emerging open codes of potential significance to the research objectives. A preliminary 
coding framework was subsequently developed and this was used to guide the coding 
of the electronic transcripts in NVivo.  
 
During the second stage of the data analysis, one member of the research team (TM) 
used the preliminary framework to code the transcripts electronically. The coding 
process was quality assured by two other members of the team (KH and MB). Any 
new themes emerging from the second stage of data analysis were discussed among 
the four team members and new codes were subsequently developed and utilised. 
This process helped to ensure that the final extracted themes were not just the 
personal interpretation of one team member but borne out of the data. Hence, the 
themes were generated without prior hypothesis (although we were guided by 
previous research) and instead relied on the inductive emergence of theory from the 
empirical data to support conclusions, in the context of a grounded theory approach 





The survey was designed in Online Surveys4, which is GDPR compliant, and at the 
end of the study the data was exported directly into Statistical Package for the Social 
Sciences (SPSS) for analysis. The quantitative data was analysed using simple 
frequency counts and cross-tabulations where appropriate. The qualitative data was 
analysed by sorting the responses for each question alphabetically (to begin the 
coding process) and reading them through carefully before finalising the codes.   
 
Similar ideas and concepts were subsequently coded into new quantitative variables.  
This fairly time consuming method facilitated the researchers to gauge the general 
weight of opinion on particular issues but more importantly to categorise the responses 
and identify different examples suitable for discussion. Verbatim quotations were 
subsequently extracted from the original variables and used to illustrate key points 
within the text of the report.  
 
Sample characteristics 
In this section we provide information about the characteristics of the people who 
participated in the study.  We begin with a summary of the interview sample and end 
with a more detailed description of the survey respondents5.  Our goal here is to 
demonstrate that our samples are credible and that we recruited the right kind of 
people with the right kind of experience (professional and/or personal) to help us 
answer our research questions.  
 
Interview sample 
Interviews were conducted with 60 people during the course of the study. Most 
interviewees were recruited through HMPPS including 29 prisoners and nine offenders 
under criminal justice supervision within the community.  The remaining interviewees 
were recruited through third sector drug treatment providers (n=11) and statutory NHS 
services (n=11).  The number of NHS patients included in the sample is disappointing, 
particularly given the lengthy process of securing National Health Service (NHS) 
                                                     
4 https://www.onlinesurveys.ac.uk/ 
5 The survey was able to ask a wide range of questions about the survey respondents whereas the interviews 
had to be more focused on the key issues in order to maximise efficiency and get the best value for money.  
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ethical approval.  The main problem that we faced was the general reluctance of staff 
in statutory services to allow us the time and space to recruit interviewees directly.  
 
Like most people engaged in substance misuse treatment in Wales, most of the 
interviewees were male (90%), white (90%) and in their mid-30s (Public Health Wales, 
2017). All of them had histories of illegal drug use and most were currently using heroin 
and/or other illegal drugs.  The majority of interviewees reported histories of 
nonmedical prescription drug use and many described current nonmedical use of 
prescription medicines. The most commonly used prescription drugs were 
mirtazapine, gabapentin and pregabalin and diazepam.   
 
Survey sample  
The majority of survey respondents were female (69%) and most were White British 
(92%) (See Table 1).  Just over half described their nationality as Welsh (53%) while 
just over one third described themselves as British (36%).   
 
Table 1  Demographic characteristics of the survey sample 
Characteristic N % 
   
Sex   
Male 22 31 
Female 49 69 
   
Ethnic group   
White British 67 92 
Other 6 8 
   
Nationality   
Welsh 39 53 
British 26 36 
English 6 8 
Other 2 3 
   
 
The survey respondents were varied in terms of the professional roles that they played 
in relation to OST (see Table 2). The largest proportion were drug workers (37%) 
followed by managers (22%), pharmacists (11%) and nurses (11%). However, the 
sample also included commissioners (5%), social workers (4%) and consultant 
psychiatrists (3%).  The diversity of roles played by respondents enabled us to explore 
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the issues from a variety of perspectives and subsequently enable us to draw a more 
complete picture of the misuse and diversion of OST in Wales.  
Table 2  Primary professional role of the survey sample 
Characteristic N % 
   
Commissioner 4 5 
Consultant psychiatrist 2 3 
Drug worker [1] 27 37 
Manager 16 22 
Nurse - prescribing 2 3 




Social worker 3 4 
Other [2] 6 8 
   
Total  74 100 
Notes: [1] Included: drug workers, outreach workers, community rehabilitation workers, recovery 
workers, peer recovery workers, substance misuse healthcare support worker. [2] Included: unspecified 
roles such as ‘third sector’, deliverers of ‘cessation courses’. 
 
Perhaps unsurprisingly given the mixture of roles played by respondents, there was 
also considerable diversity in terms of the type of organisation that survey respondents 
worked for (see Table 3). More than half (57%) worked in the third sector for voluntary 
organisations, while one-fifth were employed by the NHS and one-tenth by HM Prison 
Service. The remainder were employed by either a Local Authority (including Area 
Planning Boards), Social Services or pharmacies.    
 
Table 3  Type of organisation 
Characteristic N % 
   
NHS 15 20 
Prison 7 10 
Probation 0 0 
Community Rehabilitation Company 2 3 
Third sector 42 57 
Pharmacy 2 3 
Social Services 4 5 
Area Planning Board/Local Authority 5 7 
Other   
   
Total  74 100 




While respondents were recruited from all seven Health Board areas in Wales, the 
Health Board areas were not equally represented in the research. Caution must 
therefore be taken when extrapolating the findings across all areas of Wales. The 
largest proportions of respondents were based in Aneurin Bevan University Health 
Board (38%) and Cardiff and Vale University Health Board (27%).  The smallest 
proportion of respondents were based in Hywel Dda University Health Board (1%). 
This disparity may in part be explained by the fact that despite obtaining NHS 
Research Ethics Comitee approval we were unable to obtain NHS Research & 
Development approval in some areas. This subsequently hindered the wider 
dissemination of the survey to non-NHS staff working in those areas.      
 
Table 4  Health Board Area(s) in which survey respondents worked  
Characteristic N % 
   
Abertawe Bro Morgannwg University Health 
Board 
5 7 
Aneurin Bevan University Health Board 28 38 
Betsi Cadwaladr University Health Board 10 14 
Cardiff and Vale University Health Board 20 27 
Cwm Taf University Health Board [1] 12 16 
Hywel Dda University Health Board 1 1 
Powys Teaching Health Board 6 8 
Other [2] 2 3 
   
Total  74 100 
Notes: Multiple responses possible as some respondents worked in more than one health board area. 
Some missing cases. [1] On 1 April 2019 Cwm Taf University Health Board changed its name to Cwm 
Taf Morgannwg University Health Board (UHB) as it took responsibility for providing healthcare services 
for the people in the Bridgend County Borough area. [2] No further details were provided for these two 
‘other’ responses.  
 
 
The survey respondents had been in their professional roles for an average of just 
over eight years 6  ranging from 6 months to 24 years. Most respondents had 
experienced at least one year in the role while one-third had at least 10 years of 
experience. The sample can therefore be viewed as a credible one with considerable 
experience to draw upon when completing the survey questionnaire.  
 
 
                                                     





Table 5  Length of time in professional role 
Characteristic N % 
   
<1 year 4 6 
1-4 years 20 29 
5-9 years 19 28 
10-19 years 18 24 
20+ years 7 10 
   
Total  74 100 
Notes: Some missing cases.  
 
At the start of the survey respondents were informed that the research was targeting 
people working in the field of substance misuse in Wales.  It also advised them that 
the research was seeking the experiences of as many people as possible with regard 
to the use, misuse and diversion of OST.  Most respondents were involved in providing 
professional support to be people in receipt of OST (70%) and approximately one-third 
(34%) of respondents were directly involved in the decision to prescribe OST to 
patients. However, some respondents were not involved directly in either prescribing 
or supporting patients (e.g. they were commissioners or managers) but they 
nevertheless had views on issues relating to OST that they were willing to share.  
 
The majority of respondents (n=33, 45%) who provided support to OST patients 
described themselves as some kind of support worker (e.g. case worker, key worker, 
support worker, recovery worker, peer worker, criminal justice worker, harm reduction 
worker). Other support roles included: nurses, prescribers, managers, supervisors, 
pharmacists, and social workers. Interestingly, when asked about the size of their 
caseload, a wide variety of answers were provided.  Among those with a caseload 
who gave a clear answer, the size ranged from 1 to “350+” with most clustering around 
the 30-50 level. Less clear answers included comments such as: “I work in a tier 2 
drop in so it varies”, “XXX workers do not have caseloads. We have lots (tens) of 






Table 6  Role in relation to OST 
Characteristic N % 
   
Prescribing and supporting 24 32 
Supporting only 28 38 
Other [1] 22 30 
   
Prescribing 25 34 
Supporting 52 70 
Other 21 28 
   
Total  74 100 
Notes: Some missing cases. [1] Including one manager who was involved in prescribing OST but not 




To conclude we have provided an overview of the methods used to answer the key 
research questions. For clarity, we described each of the two main methods 
(interviews and questionnaires) separately and provided details of how the data 
generated by each method were analysed.  We then ended by presenting information 
about the characteristics of the two samples of participants that both methods 
generated.  In the next part of the report we present the results.  First, we present 
findings from the interviews that were conducted with 60 people who had recent lived 
experience of POM/OTC/OST misuse and diversion.  After this we focus on the online 
questionnaire survey and summarise the data provided by the 74 professionals 
involved in the commissioning, managing and delivery of OST in Wales.    
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4.0 Results – qualitative interview study 
 
In this chapter we present the results of our analysis of the 60 interviews conducted 
with people with lived experience of NMPDU. The interviews covered a range of issues 
including: the sources of prescription medication, patterns of NMPDU, motivations for 
NMPDU, and the methods of (and motives for) prescription drug diversion. The results 
are therefore structured as follows: sources of prescription medication for nonmedical 
use, patterns of NMPDU, motivations for NMPDU, methods of prescription drug 
diversion, and motivations for prescription drug diversion.  The chapter ends with a 
short section that examines the misuse of over-the-counter (OTC) medication. The 
imbalance in the presentation of data on prescription medications compared with OTC 
reflects the fact that few interviewees engaged in OTC misuse and hence there was 
comparatively little data to analyse and discuss.  
 
Sources of Prescription Medication for Nonmedical Use 
Our data revealed two different sources that were commonly used to obtain 
prescription-only medication for nonmedical use. These included (1) the medical route, 
and (2) the social route. These will be discussed in turn below, with reference to 
relevant quotations.  
 
Medical route  
The first route through which participants sourced medication for nonmedical use was 
the medical route. This involved participants obtaining medication illegitimately from 
the medical system. Within this source, it was possible to identify three common 
techniques through which medication could be obtained.  
 
The first was faking symptoms, or malingering. This involved presenting to a 
medical professional with an invented or exaggerated injury/illness, or relaying 
symptoms learned from others. This was by far the most widespread technique within 
this route. The following examples demonstrate how participants were able to fabricate 
certain injuries or convey symptoms gathered from others to doctors, in attempts to 




“Yeah, I could go over health tomorrow and just say, look I’m feeling 
a bit down or someone can tell me what their symptoms are, and then 
say, I’m a bit down, a bit anxious, a bit this and that, and they’d 
prescribe them to me (Prison 7)” 
 
“Yes, some people I can see doing that but sometimes healthcare can 
clock on to it, it depends on what you mention in the appointments.  
So they clock on to certain key words like I’m suffering with this and 
this and this, I’ve got pain in this, and this, and this.  Is there any 
chance you can put me on something like this?  They’ll be right, that’s 
triggered off all these red flags and their alarms, so we’ll put you on 
the other end of spectrum which you can’t abuse and misuse.  Yeah. 
(Prison 4)” 
 
The second method involved requesting specific doctors who participants knew 
would be more willing to prescribe them medication. Commonly known as ‘doctor 
shopping’, participants detailed how they would seek out doctors who they had either 
previously established rapport with (and were therefore known to prescribe 
medication) or who they knew would be more lenient in their assessment of symptoms: 
 
“Yeah, some doctors would question more than others, but I knew 
which doctors I could, I had better rapport with shall I say? (Prison 8)” 
 
“The ones which I knew that I could go in, and, they’d say, right, what’s 
the matter with you?  Blah, blah, blah, here you go (Prison 8)” 
 
The final technique – although far from common – was a reliance on corrupt or 
unscrupulous doctors. This included doctors who knew a patient was malingering, 
or doctors who would provide prescription pads to that a participant could obtain any 
medication they required: 
 
“I know people in big cities, like Cardiff and Swansea, I know doctors 
that’ll give you a prescription pad. You can write your own 
prescription out. … I’ve seen a doctor in a dealer’s house, same as 
me, because he’s on heroin as well (Prison 9)” 
 
Social route 
The second route – termed the social route – involved obtaining medication though 
friends, family and other people who use drugs. This was found to be the most 
common technique through which participants sourced medication for nonmedical 
use. Indeed, there were multiple comments from participants about the ease through 
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which medication could be obtained through these social networks. This was because 
for many participants it was unethical to leave a peer stranded or unattended in 
situations where they required medication (for example, withdrawal). It was therefore 
relatively simple to attain any medication, at any time, from friends and other people 
who use drugs. Fellow peers therefore made up a network of care and support that 
could be drawn upon in times of need: 
 
“(We take care of each other. We try to. If they know I'm bad, they 
won’t leave me out’ (Prison 10).” 
 
“If I can’t sleep, I’ll get on the phone and I’ll be like, listen boys, 
have you got any spare tablets for sale? Do you want to sell me 
some Valium? Do you want to sell me some? (Community 12)” 
 
Interestingly, the internet was rarely mentioned as a source, possibly because 
participants did not have the resources or time to access or source medication online. 
Furthermore, the ease through which participants could obtain medication from a 
friend or family member was often more convenient, and even quicker. In this example, 
obtaining medication from the internet was done so only because access to a 
legitimate supply had been restricted: 
 
“I had a prescription right at the beginning but because I abused the 
trust of the doctor, he went no.  So then I started buying them off 
the internet and then just buying them off the streets.  It just spiralled 
from there then (Prison 5)” 
 
Patterns of NMPDU 
Once medication was sourced, we were interested to investigate the multiple ways in 
which medication might be nonmedical use. This included how it was consumed in a 
way other than directed by a health care professional. Here, we identified four common 
forms of consumption 
 
The first related to quantity of the medication consumed. This form of nonmedical 
use involved consuming more than the recommended dose. In the example below, the 
participant has obtained two weeks worth of diazepam. Rather than adhering to the 
prescribed dosage, he has chosen to consume well above the recommended dose 




A  … he gave me 84 Diazepam. It’s meant to last me two 
weeks. 
Q  Okay. … How long did it last you?  
A About three days. I ate them all! I ate 15 as soon as I 
walked out the chemist! (Community 2) 
 
The second form of nonmedical use related to how the medication was actually 
consumed. It was common for participants to crush and either sniff or inject the 
substance to achieve a more rapid onset of effect. This practice was particularly 
widespread among those who nonmedically used prescription opioids, as this example 
here refers to:  
 
… “The Espranors yes, because they're quick, dissolve on the tongue.  
Yes, they're being sold as well, and sniffed. … a lot of people who 
have subbies … Yes, they crush it like you're doing a line of coke, 
crush it down with the tablet, chop it up with the card and sniff it 
as a line” (Community 11) 
 
Some participants also combined their medication with other substances. This 
was done for either one of two reasons. This first was to enhance the effects of an 
illicit substance, perhaps if the quality of it was not good enough to achieve a 
sufficient high. For example, some interviewees referred to occasional occurrences of 
poor-quality heroin that would either prolong withdrawal symptoms or increase the risk 
of them occurring. Sedatives and tranquillisers were often used to potentiate the 
effects of heroin in these scenarios. It was not uncommon, for example, for 
benzodiazepines to be used alongside quality heroin in such situations to enhance its 
effect and reduce withdrawal symptoms throughout the day: 
 
 “In London I wouldn’t have done more than a 0.2….Then when I 
came here it weren’t doing it, I was having to eat Valium’s on top.” 
(Community 2) 
 
A small number of participants noted how they would combine certain medications to 
enhance their effects. Pregablin and gabapentin were often used alongside OST 
medications, particularly in prison settings, to achieve a psychoactive effect:  
 
 Q Did you mix it [espranor] with any other drugs? 
 A Gabbies, yes, gabapentin. 
 Q What effect does that have, mixing the two? 
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 A It just gives you more… you don’t get no high off it, just more  
  energy I suppose. (Prison 10) 
 
The final method related to if the actual dose of legitimately obtained medication 
they were on was too low. In these scenarios participants were found to use an illicit 
substance ‘on top’. For example, methadone dosing usually begins at an initial daily 
dose of 10-30mg, before titration onto an optimal stabilisation dose (Clinical Guidelines 
on Drug Misuse and Dependence Update 2017 Independent Expert Working Group, 
2017). Consequently, there is a potential for initial under-dosing which may induce 
withdrawal symptoms (Faggiano, Vigna-Taglianti, Versino, & Lemma, 2003). During 
these periods, using on top was understood to be motivated largely by the need to 
supplement insufficient doses of OST 
 
“They work you up to whatever you feel that you need to be on.  So 
in the beginning it was 30 and then it slowly increased.  It wasn’t 
sustaining me at all, so I had to have the heroin on top, 'cause I had 
such a high habit, so 30mls of methadone didn’t touch the sides. 
When it got to an amount, 90mls, like I say, was the highest I was on, 
so that was comfortable for me at the time.  But until I got up to that 
point it was a case of having to take the heroin as well.” (Community 
3) 
 
Motivations for NMPDU 
The third part of our analysis related to the motivations for NMPDU. Here, two broad 
motivations/justifications emerged that can help us understand why people may 
nonmedically use prescription medication. 
 
The first of these related to recreational motives. The number of accounts from 
participants specifying that they had used prescription medications for these purposes, 
however, was limited. Indeed, it was rare for individuals to state that their primary 
motivation was to ‘get high’ from any prescription medication.  Nevertheless, a small 
number of prisoners we interviewed did report that they used for recreational 
purposes, often as a way to escape reality or pass time while imprisoned.  
 
“I do buy prescription medication every now and then, it’s not abusing 
it, it’s just every now and then I feel like I fancy a day out from reality 
really.  So I’ll buy something like pregabalin or gabapentin, or one that 
I’ve just recently found is carbamazepine, that’s a day and half out 




However, on the whole there was little evidence of our sample misuing for recreational 
purposes. Instead, participants were far more likely to report nonmedical use for 
therapeutic purposes. Often, this was for one of two reasons: (1) to relieve a 
legitimate injury or illness, or (2) to mitigate withdrawal symptoms, (if they were unable 
to obtain their primary illicit drug, such as heroin, for example) 
 
When looking at these motivations in more detail, we found that they were often linked 
to difficulties in obtaining medications from healthcare professionals. For example, 
many participants stated how it had become increasingly difficult to obtain certain 
medications over the last year for legitimate medical reasons - in particular pregabalin, 
gabapentin and diazepam. Limited access to these medications – both in community 
and prison settings – often meant some interviewees sought out prescription 
medication through alternative routes. (‘I couldn’t get the Valium off a doctor, so I was 
buying the MSJs (diazepam)’ (1 Community)). One interviewee explained how a 
serious neck injury caused him persistent pain requiring medical treatment. After 
having his gabapentin prescription terminated by a new doctor due to his status as 
‘drug user’, he chose to self-medicate with gabapentin obtained from the black market:  
 
“Yes, I didn’t have a choice really. I was prescribed them 
[Gabapentin], then they took me off them, so what did they want me 
to do? Just lie there in pain?” (Prison 1) 
 
Another interviewee explained how his pregablin prescription for an anxiety-related 
issue had been reduced and eventually terminated following entry into prison. In the 
absence of medication, he chose to self-medicate with alternatives. This included 
street tranquillisers (‘MSJs’) and street Xanax sourced from other people who use 
drugs: 
 
“It was fine, prescribed.  It dealt with all my anxiety issues, all the 
problems that I’m suffering with now, it dealt with it all.  I got here on 
the promise that I’d be on maintained meds and inside of six weeks I 
was battling.  I’d already been halved the dose and they slowly but 
surely… they’ve taken it from me. It’s a directive by the prison, not of 
the national health, it’s a prison, and it’s a major issue.  Because what 
that’s done is forced me into self-medicating, and using all the bulls***t 
and all the other things that are causing major problems in the 




Protecting oneself from opioid withdrawal was most participants’ main priority. 
This was found to be a further motivation for nonmedical prescription drug use among 
this group. To mitigate the chances of withdrawal occurring, interviewees often 
procured and stockpiled excess doses of methadone – either from their own or a peer’s 
weekend take-home supply  
 
‘f*** me, they're on some giant scripts, man. It’s like, why do you want anything else 
bar that? They're on some giant scripts, and I know for a fact they're probably not 
taking all that” (Community 7).  
 
This could then be used as a ‘safeguard’ in the event of withdrawal (Harris and 
Rhodes, 2012, p.46) participant noted that, among his peers, diverted methadone was 
a useful alternative if heroin was unavailable:  
 
“They buy it as a backup, so days that they think they can’t get 
anything, they can take it, or if they're ill that morning and the dealer 
isn’t on ‘til God knows what time, two o’clock, for some reason or 
another, then they can take that and they know they're going to be 
alright until they get some.” (Community 7) 
 
Similarly, one interviewee referred to a situation where illness prevented her from 
leaving her house to obtain heroin from her usual dealer. Her stockpiled dose of 
methadone helped control her withdrawal symptoms until she had recovered from her 
illness and was able to source illicit heroin again: 
 
“Yeah, it’s like for rainy days, I see it with people, they get it for rainy 
days.  If they can’t do graft, or well they’re not feeling well.  We go 
through times where we actually don’t feel well, as normal not feeling 
well, do you know what I mean?” (Community 8) 
 
Methods of diversion 
The third theme that emerged from the analysis was ‘diversion’.  Many of our 
interviewees had either diverted their own medication to other people or received 
medication from others. Here, a range of techniques were used to generate supplies 
of medication ready for diversion. Our analysis found that some people were allowed 
to consume their medication (including OST) unsupervised and were allowed to take 
home supplies to consume when the need to (e.g. at weekends).  Diversion of these 
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take-home supplies was commonly reported.  It was not only OST that was diverted 
in this way but other medications too (e.g. gabapentin): 
 
“I know someone in here who is on gabapentin and he had to pick 
them up once a week.  So he had the first week’s load and he put 
them in his cupboard and didn’t use them, he got the second week’s 
load and then started selling the first weeks”. ... (Prison 4) 
 
Q But just quickly, methadone, how would divert that. 
A From here, they give you your weekend dose, you take it home... 
(Community 13) 
 
In many cases, people are supervised when they are given their medication.  This is 
common practice in relation to OST.  However, our interviewees described that poor 
supervisory practices meant that they were able to take away supplies that could be 
diverted.  Indeed, we heard many times that some nurses (particularly in one of the 
prisons) would not supervise the process properly (e.g. they would turn their backs or 
not ask to see their hands or in their mouth).  It was widely known who these nurses 
were and when they were on duty, diversion was more likely to occur: 
 
“They don't check properly.  … Every day, if you wanted to keep your 
meds, you can keep them.  It all depends what nurses you can do it 
with and who you can't do it with.” (Prison 11) 
 
“Now and then, now and then.  Not every day but if you went 14 days 
a week, morning and afternoon, maybe nine times they might quickly 
ask you to open your mouth which is fine.” (Prison 12) 
 
… “There’s only one or two nurses who actually watch you do it, make 
you drink a cup of water” ... (Prison 13) 
 
One interviewee observed that the more experienced nurses were less rigorous, 
perhaps because they knew that diversion would happen regardless of them checking. 
This interviewee speculated that such nurses might actually be trying to do the right 
thing by letting them take it away to perhaps consume at a different time of day (e.g. 
when they’re not about to go to the gym) or to swap for another medication that they 
were not currently getting from a doctor.  
 
“No, there’s inconsistencies, there always will be, won’t there?  But it 
wouldn’t surprise me if the more experienced ones think, if they want 
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to get it back, they’re going to get it back.  That’s probably what’s 
happening, the old school nurses, there’s not even no point, 'because 
if he wants it back, he’s going to get it back.  That’s the reality of it.  
Or, if the nurse catches the person, there’s riot because he’s pissed 
off his meds, then it causes more problems.  She might be aware he’s 
got mental health issues and she’s just trying to do the right thing.” 
(Prison 2) 
 
While poor supervision was a good opportunity for diversion, alternative and more 
innovative methods were also described by participants. Several participants stated 
how OST medications and other prescription medications were sometimes held back 
in the cheeks (for oral solutions) or mouths (for tablet based formulations) or 
swallowed and late regurgitated. These unhygienic ‘spitbacks’ (Fountain et al., 2000) 
were then sold or shared with other people who use drugs: 
 
“People keep it. They literally just walk off with it in their mouth. … If 
a Governor pursues them, if they have to they’ll swallow it. Nine times 
out of ten they’ll make it to the closest cell they can, spit it into a cup 
or something. It’s horrible I know, it’s what they do.” (Community 2) 
 
Q So with the co-codamol and the DHC’s, are they getting 
prescribed loads of them and they can take them into their cells? 
A No, no, they just, they dose, they like keep it, hiding it, and then 
like coughing it back up or like that way. (6) 
 
“The potential harm that this might cause to the person who would go 
on to consume. Some recognised the harm this could cause. How 
people can do that, out of people’s mouths and that, because of Hep 
C and that.” (Prison 2) 
 
The potential harm that this might cause to the person who would go on to consume 
was recognised (How people can do that, out of people’s mouths and that, because 
of Hep C and that. (10)), but it was often disregarded: 
 
… “If people are bad they’ll do anything, won’t they? They don’t care.” 
(Prison 1) 
Motivations for diversion 
Finally, we asked those who were involved in diverting medication why they did this.  
The motive of helping others was commonly reported and this usually involved sharing 
supplies rather than selling them. For example, sharing doses of take-home 
methadone was a relatively common tactic to reduce a fellow peer’s withdrawal 
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symptom. In the example below, an interviewee detailed how he would take the 
minimum dose of his take-home supply to cover his withdrawal symptoms over a 
weekend. The surplus medication was than shared with his partner to cover her 
withdrawal symptoms over the same period: 
 
“You can take it home on the weekends and some nights, if you're not 
using, you're on 80ml of meth, you take 80ml of meth on a Friday and 
they say it will cover you for 24 hours but it covers you for longer.  I 
reckon it covers you a good 36 hours. So I could take my Friday's 
meth and I'm going to be alright until the Sunday so I won't have to 
use my Saturday’s then so I give that to her.  She won't take it all at 
once.  She'd split it down to three and three or 4x20ml and add it on.” 
(Community 11). 
 
Interviewees often relied on one another in a similar way to supply medication for their 
health care reasons. These relationships were particularly effective in prison settings 
where prescription medication from healthcare professionals was often hard to come 
by. One participant detailed how he would share his medication with his neighbour to 
help alleviate his medical problems:  
 
“My next door neighbour does it because he’s got sleeping problems 
as well, he’s on sleepers but his aren’t as affective as mine… I won’t 
sell them to him, I’ll say, here you go, hack on that because I get them 
every week and I can forget to take them sometimes....” (Prison 4) 
 
Key to these relationships was a sense of mutual obligation. Participants were open 
to helping someone, but usually this was only on the basis that this help was reciprocal. 
Maintaining a generous reputation was therefore an effective method of preventing 
future withdrawal, as participants were willing to assist someone who would 
reciprocate in future times of need (“If I was on a script of Valium or anything like that, 
yes, I'd give people because they give me”, (Prison 5)). One particular method involved 
‘fronting’ (i.e. advancing medication to someone else) or passing on surplus 
medication obtained from weekly pick-ups to someone else in need. This approach 
offered insurance against future withdrawal symptoms, as it enabled the sharing to be 
reciprocated at the end of the week when their medication ran out:   
 
“I mean especially when I was using more than I should have been, 
trying to make sure I had enough for the end of the week.  The best 
way to do it was to lend someone some, so at the end of the week 
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they can lend me some, so give me back and then I knew I’d have 
some at the end of the week.” (Prison 6) 
 
The above examples demonstrate how social networks play an important harm-
reducing role in a context of limited access to various prescription medications. 
Sharing prescription medication also had pragmatic necessity, however; in prison 
settings medications were valuable commodities that could be exchanged for material 
gain. Sharing and trading certain medications therefore played an important function 
in obtaining necessity goods for everyday use. This often included food, vapes, 
toiletries or other luxuries requiring financial resources (“I’d trade it for other things 
what I needed, or if I needed like a bag of sugar or something like that from the 
canteen. Oh, get me a bag of coffee and a bag of sugar, I’ll give you something to stop 
you being ill” (Community 12)). This trading was largely driven by the limited economic 
resources of those within the prison system:  
 
“Yes. It’s only because we don’t get enough money in here. If you 
haven’t got family out there to look after you and all that, that's the 
only way you can get stuff. Shower gel, toothpaste, just essential stuff 
you need, otherwise you can’t afford it. You’ve got a choice, you can 
either use the phone, or be able to brush your teeth or something, or 
have a shower.” (Prison 1) 
 
“Yeah, it’s always [trading]… someone might want some canteen, 
someone might want a packet of vapes, some people might want 




In addition to questions about prescription medications, interviewees were also asked 
whether they had previously misused over-the-counter medication (OTC). On the 
whole, misuse of OTC was limited. Our data identified two main reasons for this. The 
first was due to the strength of OTC medications. Most participants stated that should 
the need to use an OTC medication ever occur (during withdrawal situations, for 
example), stronger prescription medications were readily available that would have a 
greater effect. For example, two participants stated how OTC medications were not 
‘the proper thing’ and would have little to no psychoactive effect. Stronger alternatives 




Q Have you ever done anything like that? 
A No, not codeine. 
Q No co-codamol? 
A What’s the point? Out there, you can get heroin and all that. 
Q So why would you bother…? 
A [Respondent affirms] 
(Prison 15) 
 
A It’s not worth it, it just doesn’t do anything, there’s nothing strong 
enough that would. 
Q Not worth what? 
A You wouldn’t be able to get high off anything you can buy over 
the counter. 
Q So it’s a waste of money? 
A Yeah, total, just doesn’t happen ever. 
Q Co-codamol?   
A No, not strong enough. 




The second, and more common reason for the disregard of OTC medications was the 
potential harm they may cause. Many participants stated how they were worried about 
lasting damage (particularly in relation to the kidneys) from the misuse of medications 
containing paracetamol, particularly at large doses which were often required to 
achieve any therapeutic effect. As such, participants largely avoided any misuse of 
over the counter medications containing paracetamol, preferring instead to find 
alternative prescription medications from the illicit market: 
 
“Co-codamol and any sort of strong painkiller they could buy is always 
paired with paracetamol, so you would just be overdosing on 
paracetamol. The amount of co-codamol you’d have to take to get any 
sort of reaction off it, you’d probably kill yourself with the paracetamol, 
so it just doesn’t happen.” (03) 
 
“I think the biggest damage, that’s going to do to you is the 
paracetamol.  Paracetamol and kidneys don’t get on, especially after 
about 1000mg.” (Community 15) 
 
“The paracetamol is 500 and you get a 10ml codeine.  If you've got a 
10 bag habit a day, you need these 240 codeine, you just think then 
that's like just over 10,000ml of paracetamol.  It wouldn't work.  You 





A small number of participants, however, did state that they sometimes misused OTC 
medications. This use was limited to periods when their primary prescription 
medication was unavailable, however. For example, if a participant had a choice 
between an OTC medication and stronger prescription medication, they favoured the 
prescription medication due to its increased strength: 
 
A Yes, I can get the dihydrocodeine every day, all day as it 
happens. But again, I've got to pay for them, and what it costs 
me to pay for that, I can get the same off Subutex, so I’ll only get 
that if there's not Subutex about.  
Q So you’ve got a choice, and you're going to go for your top 
choice. 
A Yes (Prison 3) 
 
Even when using OTC medications, participants were wary of any potential harms. 
Participants often extracting the paracetamol out of Co-codamol tablets prior to use as 
a tactic to reduce harm: 
because of the paracetamol. I’d do 20 dihydrocodeine. You can 
drain the paracetamol out of it. 
Q Do you do that? 
A I have done, but if you do too much of that, it gives you bad 
stomachs. (Prison 3) 
 
Due to the perceived harms associated with excessive paracetamol use, most 
participant experiences of OTC misuse were limited. As such, there is limited data 
from our interviews in relation to this topic. Most participants simply disregarded the 
idea of OTC misuse, preferring instead to use readily available prescription 
medications which they perceived to be stronger and less harmful. Where use did 
occur, this was only as a last resort, or as a replacement for prescription medications 
that could not be sourced. Even then, participants were found to wary of any harmful 
effects, and relied on methods to reduce any potential harms.  
 
Summary 
Our data revealed how motives for NMPDU were often driven by therapeutic rather 
than recreational motives. For example, NMPDU often occurred in response to a 
legitimate medical concern in the absence of medical care or attention. This included 
the use of certain medications to relieve a legitimate injury or illness, or to mitigate 
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withdrawal symptoms, (if participants were unable to obtain their primary illicit drug, 
such as heroin, for example).  
 
Difficulties in accessing medication from a legitimate source – i.e. a healthcare 
professional – was therefore found to be a key factor in NMPDU; limited access to 
medications, insufficient dosing, and barriers to accessing treatment – both in 
community and prison settings – often meant some interviewees sought out 
prescription medication through alternative routes, or used innovative (and often 
harmful) methods to divert medication to others in need. Indeed, NMPDU was often 
enabled in these situations through a reliance on peers and other people who use 
drugs: in the absence of legitimately obtained medication, the sharing and distribution 
of medications among peers emerged as an alternative form of support that was used 
to reduce harm.  Interestingly, few interviewees reported the misuse of OTC 
medication. The general consensus was that the potential risk of harm far outweighed 





5.0 Results – online questionnaire survey 
In this section we present the results of our analysis of the 74 survey responses. The 
results are separated into two broad sections. The first examines ‘misuse’ of OST, 
which we defined in the survey as “a patient’s incorrect or improper use of their own 
prescribed OST (e.g. not following instructions, using a different method of 
administration than advised, mixing with other substances, etc.)”.  The second section 
focuses on ‘diversion’ of OST, which refers to the passing on (either through gifting, 
trading or selling) of OST medication to other people.  
 
1. Misuse of OST 
To gauge the perceived prevalence of OST misuse, we asked respondents to tell us, 
to the best of their knowledge, whether they thought that most, some or none of the 
patients receiving OST through their organisation misused their OST. The majority 
(90%) of respondents thought that at least some patients in their organisation misused 
their medication. About one-tenth (12%) thought that most patients misused their OST 
while more than three-quarters (78%) thought that some of them did. Only a small 
number of respondents thought that patients in their organisation did not misuse their 
OST medication.   
 
Table 7  Prevalence of OST misuse 
Characteristic N % 
   
Yes, most of them 9 12% 
Yes, some of them 58 78% 
No, none of them 7 10% 
   
Total  74 100 
Notes: Misuse = incorrect or improper use of their own prescribed OST (e.g. not following instructions, 
using a different method of administration than advised, mixing with other substances, etc.). 
 
When asked how often they thought patients misused their OST, the sample was fairly 
evenly split.  Just over half of respondents (57%) thought that misuse occurred 
‘sometimes’ while just under half (43%) thought that misuse occurred more frequently 





Table 8  Frequency of OST misuse 
Characteristic N % 
   
Sometimes 38 57% 
Often 27 40% 
Always 2 3% 
   
Total  67 100 
Notes: Among those who thought that misuse occurred among patients within their organisation. Misuse 
= incorrect or improper use of their own prescribed OST (e.g. not following instructions, using a different 
method of administration than advised, mixing with other substances, etc.). 
 
Types of misuse 
Those respondents who indicated that patients in their organisation were involved in 
the misuse of OST were asked to describe the types of misuse that they believe take 
place.  Respondents were advised that there would be separate questions on 
‘diversion’ and to focus on types of ‘misuse’.  Nevertheless, nearly half of those who 
provided descriptions included diversion for financial gain as a type of misuse. 
Sometimes this was alongside other types of misuse but on other occasions it was the 
only type of misuse identified.  A full discussion about diversion and related issues is 
presented later in the report.  
 
Diversion aside, the most commonly reported type of misuse was the use of other 
drugs (legal or illegal) ‘on top’ of prescribed OST, which was mentioned by more than 
half of those who provided an answer. Using on top was described in simple terms by 
many respondents (e.g. ‘on top use’, ‘using other substances’, ‘using on top’).  
However, some were more explicit and described the types of drugs that they believed 
were used on top of OST.  In some cases the type of drug was generalised (e.g. ‘using 
illicit drugs on top of prescribed medication’) while in other cases the specific drug type 
was mentioned:  
 
“Some continue to use Heroin, opiate based pain killers alongside their OST” 
  
“Continue to use opiates and not tell staff” 
 
“Abuse alongside other prescribed medicines such as pregabalin and 
gabapentin” 
 





The consumption of different dosages of OST than prescribed was another commonly 
reported type of misuse.  For many this kind of misuse was linked to under 
consumption, where patients consumed less than they had been prescribed. It was 
understood that such behaviour enabled patients to save their supplies of OST for use 
at a later date.  Sometimes this was described as a method for creating supplies for 
diversion (e.g. ‘Diversion.  If on take outs, not utilise the full daily dose’).  On other 
occasions, however, using lower dosages was described either as a means of 
facilitating the use of illegal drugs that could not be used safely on top of full doses 
(e.g. ‘take small amount so they can use Heroin on top’) or to create reserves for use 
in times of short supply: 
 
“People will leave their OST aside on days when they have heroin so they have 
a fall-back when supply is more problematic”  
 
“Stock pile in case of emergencies” 
 
For others, misuse in terms of dosing was described in terms of over consumption or 
use of a larger dose than recommended. This activity was often linked to unsupervised 
consumption of take-out supplies, which gave patients the opportunity to use more 
than recommended by the prescriber. For some, this was thought to involve patients 
consuming all of the OST that they had been prescribed earlier than planned: 
 
“If on enhances pick-up e.g. twice weekly they may take their doses early.” 
 
“Double dosing with taking away doses” 
 
“I have had some patients take all of their weekend methadone on the Friday 
and subsequently admitted to hospital.” 
 
“Use weekend doses early” 
 
For others, however, patients were understood to save up their supply (take-home or 
diverted) in order to consume at a later point in time. One respondent described that 
stockpiled OST might form part of a binge on a ‘cocktail’ of different drugs: 
 
“Some clients will stock up their OST and have a binge using it to have cocktail 




Another less commonly reported type of misuse was the use of a different method of 
administration than had been recommended. This usually involved either injecting or 
snorting buprenorphine rather than swallowing it (e.g. ‘break down the buprenorphine 
to snort’, ‘inject their subutex’).  Only one respondent referred to misuse in terms of 
use for a purpose other than intended and no specific details of what this other purpose 
was were provided.  
 
Reasons for misuse 
When asked what they thought the reasons for misuse were, some interesting themes 
emerged, some more frequently than others. Particular interest of these themes were  
the widely-held belief that misuse (which related mainly to under consumption) was 
driven by the need to generate money (e.g. ‘money’, ‘financial’, ‘sell for profit’, ‘to make 
money’). Several respondents explained that the need for money was to facilitate the 
purchase of other preferred drugs: 
 
“I think the primary reason is so they can sell to get heroin which is their 
preferred drug.” 
 
“Financial gain. To subsidise their heroin habit.” 
 
“To purchase illegal substances, or to make money for personal gain.” 
 
While many recognised the financial motivations associated with under consumption 
of OST, some understood that it was also a useful way of generating reserves for later 
use. Building ‘safety stock’ was seen as an important way of protecting against 
withdrawal symptoms in the event of limited access to OST or alternative illegal drugs 
in the future. Some respondents recognised that patients worried about missing 
appointments and being unable to collect their scripts for various reasons.  Others 
thought that patients feared being discharged early from treatment and needed 
supplies to prepare for such eventualities. They therefore used less than prescribed in 
order to generate reserves for future use.  
 
“I think some worry they may miss an appointment so in effect stock pile.” 
 
“Planning for the future-   Back up plan in case they cannot get to pharmacy” 
 
“…believe they have missed a collection therefore their prescription will be 




One respondent explained that stockpiling provided a back-up for those who were 
engaging in their own self-managed treatment programmes. This process would 
enable them to reduce and increase their dose on a needs basis:  
 
“Reducing self as current treatment options limit your reduction and does not 
allow you to go back up if you feel you need to without another assessment and 
additional support options.” 
 
Misuse in terms of using ‘on top’ was often explained in terms of pleasure seeking and 
the need to obtain a different or better effect than their OST script was offering.  This 
was often expressed in terms of patients wanting a better ‘high’, ‘hit’ or ‘buzz’.  One 
respondent explained this in more detail stating that ‘heroin has a better effect and 
they feel like having a better effect sometimes’. Another attributed the need to use on 
top to the qualities of OST, which sometimes made patients ‘feel sick’ if consumed in 
one go.  
 
Another commonly understood explanation for misuse was linked to the effectiveness, 
or rather ineffectiveness, of OST treatment.  For most, this was related to doses being 
too low and hence insufficient to stave off withdrawal symptoms (e.g. ‘dose is too low 
to hold them’, ‘Not on an appropriate dose’, ‘not prescribed at high enough levels’, ‘not 
holding the cravings’.)  However, for some respondents, the problem was less about 
insufficient dosages and more about the limited provision of holistic psychosocial 
support alongside prescribed medication. Indeed, the Clinical Guidelines (2017) state 
that “Treatment for drug misuse should always involve a psychosocial component to 
help support an individual’s recovery” (p.47) and “An integrated approach using 
psychosocial skills and interventions along with prescribing allows care to be managed 
in a way that incentivises recovery, harnesses motivation, and supports harm 
reduction and relapse prevention” (p.57). One respondent was clearly in tune with 
these recommendations: 
 
“OST is one treatment option to address opiate dependence and does not in 
itself address the social and ingrained behavioural challenges associated with 




Other respondents also flagged up the importance of providing counselling and the 
need address the root causes of dependence: 
 
“Because the primary addictive behaviour has not been adequately treated” 
 
“I know that people can still use on top/ sell their OST. This happens mainly as 
they are not receiving the proper help to stop e.g. - psychological help. There 
is too much focus on medication for treatment and not enough on the 
counselling side of things so people get to understand why they use/ or how to 
stop relapsing. I say this from my own personal experience.” 
 
“Lack of mental health/counselling support” 
 
Interestingly, misuse as a result of treatment failure was not always due to perceived 
sub-standard provision.  In some cases, treatment failure was believed to be because 
patients were not ready or not sufficiently motivated to stop using other drugs (e.g. ‘not 
ready to stop using opiates’, ‘not ready to make the change’, ‘not ready to make 
changes.) 
 
Less commonly reported motivations for misuse were linked to the often stressful lives 
of patients in receipt of OST.  Some respondents referred to the ‘stresses of daily life’ 
and the ‘chaotic lifestyles’ of OST patients. One respondent commented on the role of 
‘boredom’ in motivating misuse of substances on top of OST. Closely linked to the 
lifestyle of patients, was the role of peer pressure and bullying in encouraging misuse. 
Several respondents flagged up that misuse was linked to the ‘social circles’ in which 
patients live and to the influence of ‘drug misusing peers and pressure within their 
social group’.  In some cases this pressure clearly related to diversion (see later in the 
report for further details) but it was evident that social pressure was also understood 
to encourage the continued use of other substances on top of OST.  
 
Risks of misuse 
After exploring the motivations for misuse, respondents were asked to comment on 
what they thought were the main risks of misusing OST.  Of concern to most 
respondents was the danger of overdose and death that can result from the over 
consumption of substances that depress the respiratory system (e.g. ‘overdose’, ‘OD’, 
‘death’, ‘DRD’, ‘drug poisoning’, ‘fatal and non-fatal overdose’, ‘respiratory 
depression’, ‘fatal incidents’).  Under consumption was also seen as problematic, 
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largely because cutting down could result in reduced tolerance, which increases the 
risk of overdose when larger doses are consumed (e.g. ‘risk of lowered tolerance if not 
taking medication as prescribed to them’, ‘tolerance change due to misuse (missed 
doses)’). 
 
A range of other health harms including fairly general concerns (e.g. ‘impact on 
physical health’, ‘effect on health’) as well as some more specific harms (e.g. ‘damage 
to circulation’) were noted. Of particular concern were the health harms associated 
with intravenous injecting (e.g. ‘injecting wounds’, ‘increase in BBVs’). Social harms 
were also recognised as potential risks (e.g. ‘loss of jobs/family’, ‘getting caught’) but 
the primary concern noted by respondents was the risk of physical harm to the OST 
patient. That said, our survey respondents also recognised the potential risk to third 
parties to whom diverted medication might be sold.  As previously noted, issues 
relating to diversion are explored in more depth later in the report.  
 
The potential for misuse of OST to jeopardise the success of treatment was noted by 
several respondents (e.g. ‘removing the potential benefit of OST’, ‘not benefiting from 
treatment, not being able to stabilise and take advantage of the OST programme’, ‘not 
allowing themselves to be on a good stabilisation dose’).  The main risk of failing to 
comply was that patients would not receive the proper support from workers (who ‘feel 
you are wasting their time’) and end up either ‘dropping out’ or being discharged from 
treatment and ‘taken off [their] script’7.  Misuse was described by one respondent as 
part of the ‘revolving door’ phenomenon where people return to treatment on multiple 
occasions after failed attempts to achieve stability or abstinence.  
 
Minimising misuse 
When asked what methods they use to minimise the opportunity for misuse, the most 
commonly reported method was supervised consumption, which involves patients 
being watched as they consume their OST. This method was closely followed by the 
use of voluntary or mandatory drug testing to check that the OST has been consumed 
and/or that other substances are not being used on top.  The use of ‘behaviour 
contracts’, the threat of discharge were also noted as methods although these were 
mentioned by only a few respondents.  Interestingly, one respondent noted the value 
                                                     
7 Issues relating to premature discharge from treatment are discussed later in the report. 
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of ‘time-limited’ OST treatment and ‘planned agreed cessation dates’.  However, it was 
not clear how such measures would serve to minimise misuse.  
 
Less draconian methods seemed to be more popular with clear recognition of the need 
to improve and optimise treatment in order to fulfil patients’ needs and prevent the 
need for misuse. This included the importance of: ‘optimum prescribing’, ‘maintaining 
regular reviews’, ‘regular therapeutic and clinical appointments with clients’, ‘good 
communication with pharmacies’, creating good therapeutic relationships and sharing 
information about misuse with partner organisations (e.g. between prescribers and 
dispensers).   
 
“Create an environment that isn't punitive so that patients feel they can be open 
and honest and discuss their misuse. In this way the named nurse and patient 
can search for a solution themselves.  Occasionally we need to return people 
to supervised doses and we only relax these in the first place if there is good 
reason.” 
 
“Good relationship with client. Good communication with pharmacies. Regular 
therapeutic and clinical appointments with clients. Proactive public information 
/ health promotion within the community” 
 
“As soon as information reaches the GDAS team about someone possibly 
misusing their OST, it is given to the clinical team and a discussion is had 
around the service user and on the plan of action which can range to return to 
supervised consumption to quick detox off the script.” 
 
The importance of extending treatment to include the provision of diversionary 
activities to alleviate boredom was mentioned by several respondents as too was the 
need to provide psychosocial treatment such as counselling to address the root 
causes of the problem.  The need for ‘support and perseverance’ was also recognised 
as critical.   
 
While many described measures for preventing misuse from occurring in the first 
place, some referred to specific harm reduction methods that might help to minimise 
the harm associated with the misuse of OST.  This included providing information 
about how best to respond to overdoses as well as the provision of naloxone kits that 
would reverse an opioid overdose.  Finally, one respondent’s answer suggested that 




“Personally, I think the black market in methadone is useful and important’.”   
Summary 
In this section we have explored professional views on the misuse of OST.  Most 
respondents recognised that misuse occurred among patients in their organisation and 
many thought that this happened regularly.  The main types of misuse identified were 
the use of other drugs on top of OST and taking more or less OST than had been 
prescribed to them. Using on top was understood to be motivated largely by the need 
to supplement insufficient doses of OST and ineffective treatment or by the need to 
experience pleasure and a different kind of buzz or high. Over consumption was often 
facilitated by take-home supplies of OST and was understood to be motivated 
principally by the need to stave off withdrawal symptoms.  Under consumption was 
thought by many to be motivated by the need to make money, usually in order to 
purchase their drug of choice.  However, it was also understood that under 
consumption was useful in that it would enable patients to build up reserve supplies of 
OST that could be used in the future when access to OST or preferred substances 
might not be possible.   
 
The potential health and social harms were widely recognised with most fearing that 
patients would overdose and die either as a result of over consumption (including 
using on top) or from under consumption and the subsequent reduction in tolerance. 
Respondents described a range of methods for minimising the risk of misuse the most 
popular of which was supervising consumption although the value of drug testing was 
also recognised. While some fairly draconian methods were noted (e.g. threatening 
discharge) respondents noted the importance of optimising treatment both in terms of 




6.0 Diversion of OST medication 
 
In this section of the report we now turn our attention to a particular kind of misuse of 
OST, namely diversion.  In this report we have defined diversion as the giving, sharing, 
trading or selling of OST to others.  We noted earlier in the report that some 
respondents referred to diversion within their answers relating to misuse.  However, 
for clarity, we have reserved our discussion about these issues until now.  
 
To gauge the perceived prevalence of OST diversion, we asked respondents to tell 
us, to the best of their knowledge, whether they thought that most, some or none of 
the patients receiving OST through their organisation diverted their OST.  More than 
three-quarters (78%) of respondents thought that their patients were involved in 
diverting their OST medication. In most cases, it was felt that diversion occurred 
among 'some’ patients with only a small proportion indicating that it occurred among 
‘most’ patients.  Roughly, one-quarter of respondents did not think that patients in their 
organisation diverted their OST mediation.   
 
Table 9  Prevalence of OST diversion 
Characteristic N % 
   
Yes, most of them 2 3 
Yes, some of them 53 75 
No, none of them 16 23 
   
Total  71 100 
Notes: Some missing cases.  
 
Among those who did believe that diversion of OST occurred among their patients, 
most (76%) thought that diversion occurred ‘sometimes’ while just under one-quarter 
(24%) thought that it ‘often’ occurred.  No respondents thought that patients diverted 






Table 10  Frequency of OST diversion 
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Characteristic N % 
   
Sometimes 42 76 
Often 13 24 
Always 0 0 
   
Total  55 100 
Notes: Among those who thought that diversion occurred among patients in their organisation (n=55). 
 
Methods of diversion 
Respondents who believed that patients in their organisation were involved in diverting 
their OST medication were asked to describe how, in practice, they thought that 
supplies were being diverted.  For the most part, diversionary practices were 
understood to involve patients obtaining their medication from a pharmacy or 
dispensing treatment provider and then passing it on to others through various means. 
Two main methods of diversion were identified.  The first, and most commonly 
reported method, was the diversion of take-home supplies of medication. Depending 
on clinical need, some patients are permitted to take their medication on an 
unsupervised basis (at weekends or weekly in some cases)8.  Patients given take-
home doses therefore have ready supplies available for diverting on to others should 
they wish to do so9.   
 
The physical process of diverting take-home supplies was thought to involve patients 
taking reduced doses of medication and either diverting the surplus or stockpiling the 
leftovers ready for passing on to others.   
 
“Often on a take home dose of medication they reduce themselves and build 
dose up to sell on to others.” 
 
“With take home doses, taking less than prescribed each day then selling or 
giving away the surplus.” 
 
“Often on a take home dose of medication they reduce themselves and build 
dose up to sell on to others” 
                                                     
8 See: Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group 
(2017) Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health: 
“ultimately, the responsibility for the level of supervision for any prescription lies with the prescriber …”. 
9 Take-home supplies can be lucrative (see next section for details) and some patients were understood to cheat 
the system by submitting false urine samples in order to achieve the status necessary to be allowed take-home 





The second method of diversion described by respondents was utilised by OST 
patients who were prescribed medication for immediate ‘supervised’ consumption. In 
such cases, diversion was facilitated by inadequate supervisory practices either in 
pharmacies or dispensing clinics.   
 
“I think if medication is not supervised properly it is fairly easy, this is certainly 
the case for non-liquid OSTs.” 
 
“Lack of supervision at pharmacy.” 
 
One respondent explained that poor supervision was sometimes the result of patients, 
taking advantage of less experienced professionals who had come to trust them after 
developing a rapport. 
 
“…poor supervision after patient builds rapport with pharmacist. Young 
pharmacists.” 
 
The methods of physically concealing OST medication were reported to vary by the 
type of medication.  While it was understood to be far simpler to conceal OST in tablet 
form (i.e. buprenorphine) it was nevertheless believed possible, and common, for 
liquid medication (i.e. methadone) to be concealed too.  ‘Palming’ tablets, which 
involves sticking tablets to the palm of your hand while pretending to swallow them, 
was described by many survey respondents (e.g. ‘palming subutex’, ‘palming of 
Espranor’, ‘palming of buprenorphine’).   
 
“Palming of their buprenorphine - so the medication either never actually goes 
into the mouth, or if it does it is removed before it has been swallowed.”   
 
Respondents also described how some patients would spit tablets out after pretending 
to swallow them. In practice, this involved hiding the tablet somewhere within their 
mouth whilst making sure that it was dry enough to stop the medicine from dissolving: 
 
“Hide tablet up inside the gum area” 
 
“Dry their mouth prior to being given OST in chemist.” 
 
Spitting was also identified as a method of obtaining supplies of liquid methadone for 




“Pretend to swallow Methadone liquid or buprenorphine tablets before spitting 
out” 
 
“Keep fluids in mouth and spit into bottle outside pharmacy” 
 
“Hold methadone in mouth to spit out soon after leaving pharmacy.” 
 
It is important to note that for both liquid and tablet OST, diversion through spitting 
would only be possible if the ‘supervisor’ did not check the patient’s mouth properly 
before allowing him/her to leave. Inadequate supervision can therefore serve to 
facilitate diversion. However, even apparently adequate supervision, where the 
patient’s mouth is checked thoroughly, is not sufficient to prevent diversion entirely. 
Indeed, many respondents described how some patients would regurgitate swallowed 
OST medication to generate supplies for diversion.    
 




“regurgitate methadone into a cup / handkerchief” 
 
Most respondents described diversionary practices that occurred after the OST 
medication had been dispensed to the patient.  However, one respondent noted that 
diversion could also occur at the point of dispensing if medication was collected by 
someone who had not been prescribed the OST (e.g. ‘someone else may collect their 
script’)10.  Presumably, diversion using this method would only be possible if the 
identity of the collector was not checked properly by the dispenser.   
 
Motives for diversion 
When asked to explain the reasons why they thought that patients diverted their OST 
medication, a variety of motives were given. Some respondents provided a list of 
several possible reasons, while others limited their response to just one. The most 
commonly reported motive was understood to be the need to make money. A few 
respondents provided only brief answers such as: ‘money’, ‘to sell for money’, 
‘finances’, ‘extra cash and profit’.  Other respondents elaborated and explained why 
                                                     




extra money was needed. Paying off debts was mentioned by several respondents as 
a key motivating factor. 
 
“Debts owed while in prison, debts owed in the community” 
    
“The currency value it holds for debt and to make money.” 
 
The need for other drugs was also frequently cited as a motivator for diversion of OST. 
In some cases it was understood that illegal drugs were purchased with the proceeds 
of diverted OST.  In other cases it was thought that diverted medication was 
exchanged directly for other illegal substances.  
 
“They want to buy the drugs of their choice” 
 
 “Sometimes to make money so that they can buy illicit substances.” 
 
“Money to buy drugs”   
 
“Exchange for other substances” 
 
 “To make money/ swap for other substances for on top use.” 
 
“Sell / swap for illicit substances.” 
 
Interestingly, several respondents referred to the need to obtain other medications, 
including other forms of OST, that they were otherwise unable to obtain.  
 
“If not on their preferred OST they may sell or swap to received desired 
substance” 
 
“To obtain other medication”  
 
Financial motivation aside, other more altruistic explanations were also described.  
Respondents believed that sometimes patients would divert their medication in order 
to share with someone, often a partner, who was not receiving OST. 
 
“To share with partners not on a script - Sometimes to help someone out such 
as partner who is not yet receiving OST” 
 
“Give to partner who isn't prescribed” 
 




“Not realising how dangerous it can be to do this and not realising it can only 
be prescribed by a doctor. They may be thinking it will help them [others] with 
illnesses such as chronic pain.” 
 
“Give to a drug using partner or friend trying to help them out” 
While diversion was clearly understood to be a choice for many patients, it was also 
recognised that diversion could sometimes be motivated by fear, bullying, intimidation 
and pressure from others, including partners. Diversion was therefore not always 
willingly undertaken by patients as some were coerced into doing so.  The implication 
was that any failure to comply with bullies would result in painful consequences 
(perhaps more painful than the consequences of withdrawing from their OST 
medication). 
 
“If they are bullied into it, intimidation” 
 
“Forced to share their OST with partners” 
 
“Sometimes they are forced to do this by abusive partners.”   
  
“They are under some sort of intimidation from a partner, or dealer.” 
 
“Hassled outside pharmacies.” 
 
“Pressure from others to sell OST.” 
 
While most motivating factors were focused on the here and now, some respondents 
noted that patients sometimes diverted medication in order to prepare for future 
difficult situations.  One respondent explained that patients might hold onto their 
diverted supply ready to sell at a time when they had no money available to pay for 
illegal drugs (Keep for when they have no money to buy illicit substances). Such 
actions are indicative of careful planning and organisational skills that are not typically 
associated with this client group [need to add something on stereotyping and stigma.] 
 
For others, however, it was understood that diversion might sometimes be due to 
patients not being ready, able or willing to engage in treatment fully: 
 
“Not wanting to consume OST.” 
 




“Unable to fully commit to recovery.” 
 
“They are not ready to change their lifestyle.” 
 
“Not ready to stop using” 
 
Risks of diversion 
Most respondents identified overdose and death as the main risk associated with the 
diversion of OST.  For the most part, the risk was viewed in terms of danger to the 
third party who consumed the diverted medication. Their principal concern was that 
the third party would overdose either due to low tolerance or due to unfavourable 
interactions with other medications and drugs that they were knowingly or unknowingly 
consuming. 
 
“Selling to somebody who has a lower tolerance.” 
 
“Overdose in opiate naïve people.”   
 
“People not seen by clinicians having a prescription therefore overdose and 
death.” 
 
“Interactions with other meds as people potentially using it have not had 
appropriate assessment.” 
 
“Overdose, street methadone or subutex which has been augmented with an 
unknown sedative.” 
 
The risk of diverted supplies being consumed by children was flagged up as a specific 
concern by a small number of respondents (e.g. ‘children/vulnerable groups could take 
it’, ‘risk to children’) 
 
Other health harms were also identified as possible consequences. This included the 
possibility of third parties using drugs for the first time and some becoming addicted 
or dependent on OST medication (e.g. ‘May bring people into drug use who haven't 
previously’, ‘third parties becoming addicted to OST’). Of particular concern was the 
potential for the spread of blood borne viruses, which could occur if the diverted 
medication had been spat out or regurgitated by an infected patient (e.g. ‘Possibility 




While harm to third parties was of particular importance to survey respondents, risk to 
the diverter was also recognised as critical. Here, the main concern was that the 
patient would experience a drop in tolerance and become increasingly vulnerable to 
overdose. There was also concern that patients would use illegal drugs (of unknown 
strength) in the absence of their prescribed OST. 
 
“Overdose, if giving away their OST and then taking a full dose.”  
 
“Risk to person taking the medication. Risk to patient not having the benefit of 
treatment and associated risks.”    
 
“Overdose of both parties.” 
 
“Lowered tolerance.  Will then use heroin as they don't have their dose of OST.” 
 
The risk of being removed from treatment programmes and losing their prescriptions 
was also identified as a matter of concern (e.g. ‘Loss of prescription’, ‘discharge from 
treatment’). 
 
Some respondents were worried that patients would become even more vulnerable as 
a result of not gaining the benefit of treatment.  One respondent flagged up the 
possibility of vulnerable patients being exploited by third parties.  
 
“People are not getting the help they need and become even more vulnerable 
than they already were.” 
 
“Risk to patient not having the benefit of treatment and associated risks. Risks 
of additional vulnerabilities of patient being highlighted to exploitative 
individual.” 
 
“Irregular dosage of medication which can lead to physical health issues.”   
 
The risk of patients getting caught for diverting their medication was highlighted by 
several respondents as too was the risk being arrested and entering the criminal 
justice system (e.g. ‘arrest’, ‘overdose and criminal’, ‘getting caught’, ‘criminality’).  
 






All respondents were asked to describe the measures they take to minimise the risk 
of diversion among OST patients in their organisation. Sixty-one respondents provided 
an answer11. Some respondents described how they would respond to patients caught 
diverting their medication, while others described their routine practice for preventing 
diversion in the first place. For both, the main methods used were: supervised 
consumption, drug testing, awareness and education, information sharing, prescribing 
different kinds of OST, and maximising the quality of treatment (i.e. optimum dosages). 
In the paragraphs below, we flag up some examples of these methods. As before, 
some respondents described using multiple techniques while others described just 
one. 
 
The provision of supervised consumption, whereby OST medication is consumed in 
front of the dispenser, was the most commonly reported method through which 
respondents tried to minimise diversion.  Most respondents described the nature of 
the supervision in fairly general terms (e.g. ‘Watching everyone closely’, ‘CCTV 
Supervised consumption’, ‘Supervision of treatment hatches’, ‘… supervised 
dispensing’, ‘Daily supervised consumption’). 
 
However, one was more specific in how he/she thought consumption should be 
supervised to minimise the risk of diversion (e.g. ‘ensuring that a full glass of water is 
drunk after issuing medication’).  Several described the importance of engaging in 
conversation with patients and asking questions about their treatment to establish the 
likelihood of diversion occurring:  
 
“Engaging in conversation, careful supervision.” 
 
“Daily supervised consumption, asking if people are taking their full doses.” 
 
“At each meeting, asking questions around their using behaviour and their script 
use. … If they complain of withdrawal symptoms or say the dose is not holding 
them, ask questions about why this might be.”  
 
“… Keeping in touch with clients” 
 
                                                     
11 The non-respondents included: 8 drug workers, 1 manager, 1 pharmacist and 3 ‘other’. 
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While communication with patients was viewed as important by some respondents, 
others also recognised the value of communicating regularly with partner 
organisations, particularly with pharmacists involved in dispensing OST to patients.  
Sharing information is critical to ensuring that prescribing regimens are followed and 
that any concerns about patients are investigated fully.   
 
“Good communication with other agencies and pharmacies.” 
 
“Liaise with pharmacy for close supervision” 
 
“Liaison with pharmacies” 
 
“Discuss with chemist” 
 
The value of urine and other forms of drug testing were flagged up by some 
respondents as a key method used to try to minimise diversion (e.g. 'regular testing', 
'random drug screening', 'urine screening'). Testing facilitates both the detection of 
treatment compliance (i.e. determining if service users have consumed their scripted 
medication) and also the use of other non-prescribed drugs (i.e. illegal drugs such as 
heroin)12. 
  
“Monitor DSUs for presence of prescribed OST metabolites! 
 
“Test frequently to make sure they have the scripted drug in their system as 
well as for opiates.” 
 
“EDDP13 testing. Urine test validation. Oral swab testing” 
 
When test results suggest that the patient is not complying with treatment, they risk 
being placed under tighter supervision, being suspended or, in rare cases, being 
discharged from treatment. Testing can therefore act as a strong deterrent for misuse 
and diversion.  
 
Educating patients about the consequences of diversion and the potential dangers of 
sharing their OST with others, was another key strategy identified by respondents.  
                                                     
12 Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group (2017) 
Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health. 
13 The test allows to screen for the effective intake of methadone by detecting its metabolite, the EDDP.   
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Some referred specifically to harm reduction while others were more general in their 
comments referring simply to the need to ‘educate’ or to provide ‘education’: 
  
“Supplying info/harm reduction” 
 
“Harm minimisation advice. Discussion of risks involved if it is suspected.” 
 
“Always discuss harm reduction” 
 
“Explain consequences of diversion” 
 
Interestingly, one respondent mentioned naloxone (‘naloxone and education’), 
suggesting acceptance of the likelihood of diversion and the importance of preparing 
for an overdose event that this might create.    
 
A small number of respondents described methods involving the OST treatment itself 
as a means of minimising the risk of diversion.  Several mentioned switching from one 
kind of OST to another.  This included switching from methadone to a less easily 
diverted substitute such as Espranor and switching to Suboxone which contains 
naloxone and is a less attractive OST for misuse and diversion: 
 
“Consider products that minimise risk. I.e. suboxone” 
 
“Using espranor instead of buprenorphine methadone instead of 
buprenorphine” 
 
“espranor - dissolves quicker.” 
 
One respondent referred to the importance of maintaining optimum dosages of OST 
to hold patients more effectively and hence discourage both diversion and the use of 
other substances on top (‘maintain optimum dosage for individuals’).  Another 
considered regular reviews of treatment plans as critical in helping to minimise the risk 
of diversion (‘review treatment plans’).  Interestingly, just one respondent commented 
on the value of diversion itself for people who use drugs.  This respondent highlighted 
the issue of waiting lists for OST treatment (which remain high in parts of Wales) and 
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explained that ‘my personal view is that diversion helps those waiting for prescribing’ 
(Welsh Government, 2019)14.  
 
Finally, several respondents suggested that they minimised diversion by using or 
threatening to use tough sanctions, such reintroducing supervised consumption, 
reducing doses of OST or removing or discharging patients from treatment. 
  
“As previous, removing prescribing where on review it appears it's being 
abused treatment consequences (discharge)” 
 
“Discharge if not compliant with treatment, this is rare mostly try to support 
client.” 
 
… “Advice that patient should diversion be seen that prescription will reduce 
and OST be stopped due to the dangers not only to the patient but to those 
receiving the medication illicitly.” 
 
“Any concerns then the patient goes to 7 day supervised consumption of 
prescription (SCOP).”  
 
Using discharge as a punishment is contrary to National Institute for Health and Care 
(NICE) Guidance, which states in Section 4.5.1 that: “The principal reason for using 
supervision is to ensure the safety of the patient and to minimise the risk of toxicity. It 
should not be used or viewed as a punishment.”   
 
Furthermore, early discharge from treatment puts patients at an increased risk of 
overdose death, contracting a Blood Born Viruses (BBV) and offending (Clinical 
Guidelines, 2017, S.4.6.5). The Clinical Guidelines therefore recommend that any 
such decision be made by the prescriber in consultation with the multidisciplinary team 
and that patients are forewarned of the potential actions that might be taken when 
treatment goals are not achieved (Clinical Guidelines 2017, S.4.6.5).   
 
One respondent provided a useful description of the delicate balance needed to 
minimise the risk of diversion while maximising progress towards positive treatment 
outcomes.  
                                                     






“You have to weigh up risk of diversion (and evidence of DRDs [drug-related 
deaths] from these) against reward to engagement and progress. A lot of 
service user’s work towards being able to reduce their collection days and it 
can be a useful tool, with service users positively marking this as progression 
into stability and normal routine. Some service users view supervision as 
demeaning and embarrassing, especially in a busy pharmacy setting. Daily 
supervision consumption is not a legal requirement. It can be noted on the 
prescription for the pharmacist to follow the dispensing instructions but it’s 
actually not legal.” 
 
 
Other issues relating to misuse and diversion 
At the end of the survey, all respondents were given the chance to tell us anything 
else about misuse and diversion of OST that had not been covered in the 
questionnaire. Twenty respondents took the opportunity to provide additional 
information, although one of these was a negative comment about the survey itself 
rather than about issues relating to misuse and diversion.  Nevertheless, even this 
respondent recognised that it was an ‘important survey’. 
 
The additional comments made by respondents were varied and covered a range of 
important issues, some of which re-emphasised points made within the questionnaire.  
For example, several comments were made about the extent of misuse and diversion 
(‘90% of OST recipients use on top, with a significant amount of methadone being 
bought and sold on the black market; many patients who attend clinic can get hold of 
OST at most times from the street if needed’).   
 
Waiting lists and difficulties accessing treatment outside of working hours, were also 
identified as factors contributing to misuse and diversion of OST (‘Often, lengthy 
waiting lists for OST is the reason why many individuals sell on prescriptions that they 
do not really want or need, for financial gain’). One respondent suggested that access 
to pharmacies be increased, presumably to reduce the amount of unsupervised take-
out supplies being issued (‘7 day pharmacies are needed throughout. mobile 
pharmacy dispensing needed’).   
 
Some respondents used the opportunity to flag up new and important issues. One, for 




£Financial implications of medication must be considered as buprenorphine 
(generic) or espranor is now extremely expensive. Where prescribing services 
have a limited budget and it costs £5000 per year per place for a service user, 
you can see how this will add up and be unsustainable.” 
 
Another respondent highlighted the complexity of achieving a consensus among 
healthcare providers when different organisations with different philosophies are 
involved in delivering OST to patients.  This respondent also noted the importance of 
assessing and managing risk properly and having proper plans in place to reduce the 
risk of misuse and diversion.  
 
“Hard to get an agreement on an approach with different 
organisations/philosophy of approach.  It is important when people start on OST 
programmes that there will be some misuse as people continue to use on top 
but this should be risk assessed and proactively managed and when the 
evidence says that the risk is no longer acceptable mechanisms should be put 
in place to reduce the risk which in this case is the prescription. The challenge 
is in getting agreement on the limits. Seeing individuals on a monthly basis for 
planned appointments means non random drug tests which are very easy to 
subvert.” 
 
Interestingly, one respondent felt that drug treatment services were well aware of the 
risks of misuse and diversion and therefore had processes in place to minimise any 
risks.  This respondent felt that misuse and diversion was more likely to occur when 
OST is prescribed within Primacy Care settings outside of Shared Care arrangements.  
 
“Where we have come across this in our area it generally hasn't been the 
commissioned drug treatment services, who tend to be aware of the problem 
and so have processes in place to minimise it. We have seen it instead where 
individual patients appear to have been able to access OST within Primary 
Care, outside of formal Shared Care arrangements.” 
 
For one respondent, diversion of OST was seen as a positive thing that could prove 
useful in several different circumstances, including cases where patients have been 
unable to collect their prescription for some reason:  
 
“I have seen many patients benefit from purchasing illicit methadone over the 
years; whether it’s clients in work who didn’t get back in time to get to their 
pharmacy, or clients falling through services due to overly strict rules; or clients 
having a treatment break and needing something to hold them longer than 




Another respondent questioned the evidence of the harm of diversion of OST. For this 
respondent, of greater concern was the misuse and diversion of General Practitioner 
(GP) prescribed medication such as gabapentinoids and analgesics: 
 
“It would be interesting to see the evidence where diverted doses have posed 
such a large and continuous risk. Generally, the largest most hazardous issue 
remains GP prescribed medication and not OST. There are large numbers of 
service users diverting their GP prescribed medications, all the gabapentoids, 
anxioytics and pain medications.”     
 
This same respondent also raised a particularly interesting point about finding a 
balance between reducing risk and facilitating recovery: 
 
“Although, clinically, supervision remains the best way to reduce risks, it is not 
always a useful tool when trying to build recovery. It interrupts the building of a 
different daily routine, limits job prospects and for some [it’s] humiliating.” 
 
In a similar vein, another respondent noted the importance of making the OST process 
more ‘patient led’ to ensure that patients are empowered and encouraged to engage 
in treatment and achieve positive outcomes. 
 
“I believe that OST is an essential tool in the treatment of substance misuse but 
I do not believe that it is the place of prescribing services to be the drink and 
drug police. The process needs to be more patient led, even at the risk of 
increasing the misuse and diversion of opioid substitution treatment. A change 
in culture to be more empowering to the patients involved will see greater 
numbers engage in treatment and an eventual fall in the misuse and diversion 
of opioid substitution treatment.” 
 
Summary 
In this section we have examined professionals’ views on the diversion of OST. More 
than three-quarters of respondents understood that at least some of their patients were 
involved in diversion but few thought that this happened very often.  Two main methods 
of diversion were noted, which included the diversion of OST medication that should 
have been consumed under supervision (i.e. through concealment) and the diversion 
of take-home supplies that were supplied for unsupervised consumption at a later 
date.  The primary motive for diversion was understood to be for financial gain, 
although some respondents recognised that diversion facilitated the consumption of 
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other preferred substances including other forms of OST and prescribed drugs as well 
as illegal drugs.   
 
Altruistic motivations were also reported, which involved patients sharing their OST 
but sometimes this was not always a matter of choice as some patients were known 
to be bullied and intimated into sharing their OST.  Most respondents were concerned 
about the potential harm to a third party who would go on to consume the diverted 
medication.  The biggest fear was that this person would overdose due to low tolerance 
or unfavourable interactions with other drugs. Concern over the welfare of those 
diverting their medication was also expressed and this was often related to worries 
about increased vulnerability to overdose following consumption of lower doses.  
Efforts to minimise diversion were focused primarily on supervision but also included 
drug testing, education, information sharing and optimising treatment both in terms of 





In this report we have presented findings from a qualitative study investigating the 
motives, patterns and consequences for the misuse and diversion of POM/OTC 
(including OST) among people who use illegal drugs in Wales. When drawing 
conclusions, however, it is important to recognise the limitations of the research. Like 
most cross-sectional studies that rely on self-report surveys of people who use drugs, 
the research is limited by issues of accuracy of recall and honesty (Neale & Robertson, 
2005). Accuracy of recall is particularly problematic in scenarios where respondents 
may be intoxicated (Bennett & Higgins, 1999). Nevertheless, in spite of these 
weaknesses, self-report is widely used in research on people who use drugs and there 
is evidence to suggest that it can produce reliable results (Dietze, Jolley, Fry, & 
Bammer, 2005). This study is also limited by the fact that the sample is biased in favour 
of participants who were willing to participate. It is possible that unwilling and 
unavailable participants engaged in the misuse of these substances do so in different 
and potentially more harmful ways that are not documented in this study. This includes 
overdose and death. Generalising the findings beyond the current sample therefore 
needs to be done with caution. 
 
Accepting these limitations, the current study provides new evidence on the 
motivations for nonmedical prescription drug use (including sourcing, consumption 
and diversion) among people who use illegal drugs in Wales, UK. This includes the 
identification of a number of motives for the misuse and diversion of a range of 
prescription medications in this specific context. It is hoped these findings will help to 
inform policy and practice and contribute to relevant harm reduction guidelines for 
people who continue to use prescription medications alongside other illegal drugs.   
 
Our data revealed a range of prescription medications that were commonly misused. 
The most commonly used prescription drugs were found to be mirtazapine, gabapentin 
and pregabalin and diazepam, all of which played different functions in different 
scenarios.  
 
Benzodiazepines and gabapentinoids, for example, were sought after medications 
that could be used to enhance the effects of poor-quality heroin. OST medications and 
other prescription opioids were found to be useful in relieving withdrawal symptoms, 
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or scenarios where heroin could not be sourced. Similarly, both interviewees and 
respondents detailed how methadone was used as a strategic ‘backup’ to safeguard 
against future withdrawal. Interestingly, participant experiences of OTC misuse were 
limited in our data. This is perhaps because most participants did not engage in OTC 
misuse, preferring instead to use the easily available prescription medications above 
which they perceived to be stronger and less harmful. As such, OTC misuse was not 
found to be a widespread issue among our sample.  
 
Perhaps the most important finding from our research however, is that the motivations 
for misuse and diversion were largely for therapeutic rather than recreational 
purposes. This was confirmed in both interviews with people with lived experience and 
in surveys with healthcare professionals. Misuse was found to be primarily to self-
medicate in the absence of certain prescription medications and treatment. Indeed, 
we found that when access to certain medications was restricted – both in the 
community and prison settings - participants sought out medication through different 
routes. This included sourcing and consuming alternatives (such as MSJs and street 
Xanax, which have become readily available in Wales in recent years) from friends 
and other people who use drugs.  
 
For some, the misuse and diversion of prescription drugs can therefore be explained 
by the need to alleviate health and social needs in the absence of legitimately 
prescribed medication, a finding confirmed by similar studies in this field in different 
geographical settings and political contexts (Harris & Rhodes, 2013; Koester et al., 
1999; Mateu-Gelabert et al., 2017; Richert & Johnson, 2015). This includes how 
limited access to medication can act as barriers to treatment and motivate some drug 
users to engage in nonmedical prescription drug use. Our data revealed how these 
certain barriers (including dosing protocols, stigma and rigid protocols on prescribing 
certain medications to people who use drugs) often led to self-medication with illicit 
alternatives. For example, many survey respondents detailed how ‘using on top’ was 
motivated largely by the need to supplement insufficient doses of OST and ineffective 
treatment. Hence, over consumption was often facilitated by take-home supplies of 





Our findings are therefore illustrative of the well-versed point that restrictive prescribing 
and treatment regimens are key forces driving the black market for these substances 
(Beletsky & Davis, 2017; Mars, Bourgois, Karandinos, Montero, & Ciccarone, 2014). 
Rather than prohibiting and reducing access to certain medications and treatments, 
tailoring treatment to individuals and improving access to healthcare might reduce the 
need for drug users to misuse and divert medication in the first instance. Lowering 
barriers to treatments and certain prescribed medications, may reduce the demand for 
prescription drugs on the black market and limit the harms associated with NMPDU 
(Johnson & Richert, 2019; Richert & Johnson, 2015) 
 
Nevertheless, the findings from this research should not detract from the risk of harm 
posed by concomitant nonmedical prescription drug use (Macleod et al., 2019; ONS, 
2019), and we recognise that proponents of more restrictive prescribing protocols may 
question calls for greater flexibility, particularly as a large evidence base currently 
exists reporting the benefits of such regimes. The supervised consumption of 
methadone, for example, has been associated with reductions in overdose mortality 
occurring as a result of methadone diversion (Strang et al., 2010). Meanwhile, US 
states with more robust Prescription Drug Monitoring Programmes (PDMP’s) were 
found to have fewer prescription opioid overdose deaths than states with weaker 
PDMPs (Pardo, 2017). Balancing legitimate patient demands with the need to prevent 
misuse could therefore prove challenging and requires further consideration before we 
can find a solution that is both safe and acceptable.  
 
Similarly, the diversion of medication among this group was primarily to help others. 
Hence, although healthcare professionals largely attributed the misuse and diversion 
of medications to financial motives, this suggestion was generally refuted in interviews 
with those with lived experience who described the POM market as being distinct from 
other illicit drug markets driven by profit. Instead, it resembled a ‘social supply’ group, 
where medication is often shared or traded for other supplies, rather than for financial 
gain. In our study, there were many examples of people sharing prescription 
medications with peers who were in legitimate medical need. This system was 
underpinned by an altruistic and emphatic bond between peers: most drug users had 
experienced withdrawal, knew how painful the experience was, and would therefore 




Nevertheless, there was often the expectation that reciprocity would occur if the sharer 
was ever in future need (Bourgois & Schonberg, 2009; Harris & Rhodes, 2013). 
Maintaining a generous reputation was therefore an effective precautionary tactic 
against withdrawal. Our findings further contribute to these arguments by uncovering 
how prescription medications can operate as a form of currency for many people who 
use drugs. This was particularly evident in prison settings, where the cashless trading 
of prescription medication enabled commodities – such as toothpaste, shower gel and 
mouthwash – to be obtained. The sharing of prescription medications therefore 
generated a number of important social and everyday benefits for this group.  
 
The complexity of prescription drug misuse and diversion underscores the importance 
of drawing on innovative and evidenced-based approaches to reducing drug-related 
harms related to prescription drug misuse.  
 
As stated above, our findings affirm the value of prescription drugs as a social resource 
among drug users (Bourgois, 1998; Bourgois & Schonberg, 2009; Harris & Rhodes, 
2013). Given that people who use drugs groups have the capacity to respond and act 
effectively in the event of drug-related harm (Holloway, Hills, & May, 2018), drawing 
on the knowledge and relationships within these networks can be instrumental in 
producing ‘cultures of care’ that ‘enhance resiliency and reduce the experience of 
harm’ (Duff, 2009: 207). This includes the peer delivery of relevant harm reduction 
messages and services (including the provision of take-home naloxone and overdose 
response training) that have the potential to reduce harm at both individual and 





8.0 Conclusions and recommendations 
 
In this report we have presented findings from a qualitative study drawing on the 
experiences and views of people with lived experience as well as professionals 
working in the substance misuse field in Wales. The research provides new evidence 
on the motivations for nonmedical prescription drug use among people who use illegal 
drugs in Wales. This includes the identification of a number of motives for the misuse 
of a range of prescription medications in this specific context. These motives were 
found to be consistent with previous research exploring the misuse of individual 
medications, including methadone (Harris & Rhodes, 2013) and benzodiazepines 
(Mateu-Gelabert et al., 2017) alongside illegal drugs such as heroin.  
 
We affirm the position of these scholars on the need to understand and acknowledge 
an alternative side of nonmedical prescription drug use that is rarely investigated in 
the literature. This includes how, (1) rigid protocols can act as barriers to treatment 
and motivate some drug users to engage in nonmedical prescription drug use, (2) 
nonmedical prescription drug use offers protective potential from many of the everyday 
risks illegal drug users are exposed to.  
 
An understanding and acknowledgement of these issues can enable the insertion of 
pragmatic solutions into treatment that attend to the immediate needs and priorities of 
some individuals engaged in nonmedical prescription drug use. This includes 
harnessing the support and knowledge of people who use drugs and members of their 
social networks who have the capacity to respond and act effectively in the event of 
drug-related harm. Whilst these measures may go some way to optimising treatment 
and service provision, we also emphasise the need for additional policy measures that 
attend to the inequities and social-structural factors that produce and maintain the 
need to consume prescription medications in ways that are not intended. This includes 
the provision of accessible, stigma-free and holistic interventions that seek to address 









The following sections provide a number of recommendations based on the findings 
of this piece of research. This includes both recommendations for clinical practice and 
harm reduction in general.  
 
Recommendations for Clinical Policy 
 
 Given the potential for harm associated with concurrent benzodiazepine use, 
co-prescribing benzodiazepines to opioid-dependent patients during OST 
should be carefully considered on an individual basis. Recent studies have 
advised against the co-prescribing of benzodiazepines to patients in receipt of 
OST due to elevated risks of overdose (MacLoed et al., 2019). Conversely, our 
findings support the notion that individuals may transition to illicit 
benzodiazepines and medications in response to restrictive prescribing 
regimes (Richert and Johnson, 2015).  We therefore urge careful assessment 
of the patient during consultation (including an assessment of whether the 
patient is using/intends to use the prescription medication for recreational or 
therapeutic purposes) and the need for appropriate monitoring and review of 
patients at elevated risk of harm from concurrent use.  
 To prevent malingering, coordinate care with other services to ensure an 
awareness of patients who are prone to the use of prescription medications for 
recreational purposes.   
 Options for the safe detox from prescription medications should be introduced 
and offered to patients with concurrent opioid dependence at regular intervals.  
 Clinicians should be aware of and provide relevant harm reduction advice to 
opioid-dependent patients about the harms associated with concomitant 
prescription drug use (see below). 
 Develop strategies to manage the use of benzodiazepines or other central 
nervous system depressants when patients begin opioid substitution therapy 
treatment. Discuss with patients how they may control and reduce their 
benzodiazepine use. 
 Ensure timely access to treatment (i.e. reduce waiting times for OST) 
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 Consider involuntary discharge from treatment as a last resort (and not to be 
used as a punishment). 
 Ensure more realistic and pragmatic rules that relate to the everyday 
complexities of opioid use (e.g. not losing access to services if late or ill). 
 Deliver messages regarding the therapeutic rather than recreational 
motivations of NMPDU outlined in this research to help eliminate stigma and 
improve treatment experiences.  
 Provision of holistic package of care alongside prescription drugs as per the 
Orange guidelines. This includes the need for additional policy measures that 
attend to the factors that produce and maintain the need to consume 
prescription medications (housing instability, homelessness, mental health 
unemployment etc.)  
 
Where individuals express a desire to continue NMPDU, general harm reduction 
principles are appropriate to NMPDU and should be relayed.   
 
Harm reduction  
 
 Provide education about the risks of NMPDU, including overdose and death, 
both when used as prescribed and when obtained illicitly. Harms associated 
with concomitant opioid and alcohol use should also be relayed.  
 Provide people who use drugs with advice on how best to taper use of 
prescription medications. The harms associated with sudden benzodiazepine 
cessation should also be reinforced.  
 Capitalise on the helping culture evidenced in this report and encourage peer-
to-peer harm reduction advice/methods. This includes the delivery of education 
and harm reduction methods (including overdose management training), 
ownership of take-home naloxone kits, and the promotion of pro-social 
behaviour that is evident among drug-using networks. In effect, this will create 
safer, peer-led drug using spaces that have the potential to reach those at most 
risk of harm.   
 To ensure that all trained prisoners receive Take Home Naloxone (THN) kits on 
release from prison. 
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 To incorporate NMPDU advice within generic harm reduction advice provided 
by a range of services (including drug, alcohol, mental health and 
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For the purpose of Appendix A, please refer to the link below that will display the 
following document:  
 
‘Drug misuse and dependence UK guidelines on clinical management’ 
 
Document title and information ‘Clinical Guidelines on Drug Misuse and 
Dependence’ this document was published in 2017 by the Independent Expert 
Working Group, Department of Health, London.  
 




The chapters below are in relation to some of the key themes listed throughout ‘Drug 
misuse and dependence UK guidelines clinical management’ document.  
 
Chapter 4: Pharmacological Interventions  
 
Please refer to Chapter 4 ‘Supervised Consumption’ (Page 101) 
 
The first section under this chapter to note is point ‘4.5.1 When and how to use 
supervised consumption’ 
 
Supervision of consumption by an appropriate professional provides the best 
guarantee that a medicine is being taken as prescribed. Following the introduction of 
supervised consumption in England and Scotland, methadone related deaths reduced 
fourfold (Strang et al 2010). 
 
The General Medical Council guidance on consent (2013) highlights that “for a 
relationship between doctor and patient to be effective, it should be a partnership 
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based on openness, trust and good communication. Each person has a role to play in 
making decisions about treatment or care”. The patient is a key partner in decisions 
on the appropriate level of supervision. Supervised consumption should be viewed as 
a situation where therapeutic relationships can be built with patients. The principal 
reason for using supervision is to ensure the safety of the patient and to minimise the 
risk of toxicity. It should not be used or viewed as a punishment. 
 
Levels of supervision should be based on an individual risk assessment for, and with, 
each patient. Clinicians and treatment providers should be familiar with opening hours 
of pharmacies that are accessible to the patient. For many on daily supervised 
consumption, providing a take-home dose for Sundays is the only practical option, but 
for others it may be feasible to access a pharmacy that opens seven days a week. 
Patients who are working can often take advantage of pharmacies that are late 
opening. It is important to consider the best option for each patient. 
 
For most cases, it will be appropriate for new patients being prescribed methadone or 
buprenorphine to be required to take their daily doses under the direct supervision of 
a professional for a period of time to allow monitoring of progress and an ongoing risk 
assessment. The risk assessment should include a review of compliance and 
individual circumstances, including whether the home environment is suitable for safe 
storage of medications. In some cases, following this, the supervision will be needed 
for an extended period while for others it may be assessed as only being needed for 
a short period. Duration of supervision should be dependent on assessed clinical need 
and should not be applied in an arbitrary way. 
 
The clinical need for supervised consumption should be reviewed regularly by the 
prescriber. Although, ultimately, the responsibility for the level of supervision for any 
prescription lies with the prescriber, decisions on when to relax or increase the 
requirement for supervised consumption should include consultation with the 
multidisciplinary team, the patient and liaison with the dispensing pharmacist. For 
example, long-term, daily supervised consumption would probably not be appropriate 
for a patient in regular, full-time work or education where supervision would be a clear 
barrier to retention in treatment and recovery. When a patient restarts methadone or 
buprenorphine after a break, receives a significant increase in the dose or during 
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periods of instability when tolerance may be reduced, daily dispensing – ideally with 
supervised consumption – should be reinstated for a period of time and reviewed at 
regular intervals. 
 
In patients whose treatment is failing, a period in supervised consumption can improve 
observation of progress and can be used alongside an increase in interventions to 
improve outcomes. 
 
The level of supervision and the frequency of collection should be based on individual 
assessment of patient needs, including the risk assessment, and should be sufficiently 
flexible to respond to changing circumstances. 
 
Particular issues arise when patients currently on supervised dispensing request 
special or exceptional arrangements for travel, holidays or family events. Patients 
should be advised at the outset of treatment that they will need to give advance notice 
of holiday, travel or other events that require altered prescribing or dispensing 
arrangements. Urgent requests will inevitably arise and services need processes to 
assess and respond to such requests. In some circumstances, even with advance 
notice, and especially for those early in treatment or significantly unstable, the 
prescriber may not feel able to safely provide a supply of medication to cover the event. 
The clinical rationale for this decision should be clearly explained to the patient.  
 
More information in relation to legal arrangements relating to travelling abroad with 
controlled drugs can be found at annexe A6 (Page 303) within the document. 
 
In most cases, the person supervising consumption will be a community pharmacist, 
although some specialist services and dispensing doctors may employ their own 
pharmacy or nursing staff to provide on-site supervised consumption. There should be 
multi-agency protocols in place to ensure a consistent high standard of service is 
provided. As part of the service, there should be systems to ensure information about 
patients can be fed to and from the prescriber and keyworker, as well as agreement 
from the patient that confidential information can be shared between the pharmacist 




The aims of a community pharmacy based supervised consumption service include: 
• ensuring the patient receives the prescribed dose 
• reducing diversion of prescribed doses 
• providing an opportunity for the pharmacist to make a regular assessment of 
patient 
 compliance with treatment and of their general health and wellbeing 
• providing an opportunity for the pharmacist to build a therapeutic relationship with 
the 
 patient that is beneficial to promote heath and harm reduction 
• reducing the risks of drug related overdose and deaths 
• Minimising the risk of accidental consumption by children. 
 
Pharmacies have expanded their services in recent years and pharmacy contracts 
have developed. Pharmacists have unrivalled expertise in the use and interaction of 
medicines and they should be used to support OST patients. Pharmacists should 
contribute to the treatment and care of patients through liaison with prescribers in the 
assessment of appropriate levels of supervised consumption. 
 
There are no universally agreed standards for supervised consumption in community 
pharmacy. However, the Pharmaceutical Care for Patients Prescribed Opioid 
Replacement Therapy standards document, introduced in Scotland in 2015, provides 
a useful template for local services (NHS Scotland 2015). These principles are based 
on the General Pharmaceutical Council (GPhC) standards for registered pharmacies, 
which apply in England, Wales and Scotland. In Northern Ireland, the pharmacy 
regulator is the Pharmaceutical Society of Northern Ireland (PSNI). 
 
The second chapter to note under the Supervised Consumption section is 4.5.2 
‘Stopping supervision’ (Page 103) 
 
Relaxation of supervised consumption and instalment dispensing should be a stepped 
process in which a patient normally remains on daily dispensing with reduction or 
cessation of supervision and progression to less frequent instalment collection. The 
relaxation of supervision and collection is an important component of supporting 
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further recovery in stable patients. It is recommended that no more than one week of 
take-home doses is supplied as a single instalment. 
 
Supervised consumption should only be relaxed once the prescriber has good reason 
to believe that compliance will be maintained. The assessment of compliance and 
clinical progress is covered in the document and in depth information in relation to this 
can be found at section 4.6 (Assessing and responding to progress and failure to 
benefit). In general, the assessment should cover: 
• compliance with prescribed drug treatment 
• abstinence from or significant change in heroin or other drug misuse 
• changes in drug-taking behaviours (such as cessation of injecting) 
• compliance with other elements of the treatment and recovery care plan, for 
example, 
• attendance at appointments. 
 
Arrangements for daily consumption through instalment prescribing and, where 
appropriate, supervised consumption of other medicines, can be made. 
 
To protect patient and community safety, take-home doses should not normally be 
prescribed where: 
• the patient has not reached a stable dose 
• the patient shows a continued and unstable pattern of drug misuse, including a 
significant 
• excessive level of alcohol intake, the use of illicit drugs and/or misuse of 
benzodiazepines 
• or other tranquillisers 
• the patient has a significant, unstable psychiatric illness or is threatening self-harm 
• there is continuing concern that the prescribed medicine is being, or may be, 
diverted or 
• used inappropriately 
• there are concerns about the safety of medicines stored in the home and possible 
risk 




The third section to note under the Supervised Consumption chapter is 4.5.3 ‘Issues 
in supervised consumption’ 
 
A range of different medications can be supervised. Oral methadone solution 
consumption can most easily be observed. Buprenorphine sublingual tablets can be 
more difficult to supervise because of the length of time taken for the tablet to dissolve. 
Some pharmacists have been crushing buprenorphine tablets before consumption to 
make the supervision process more straightforward. This practice, while technically 
off-licence, may sometimes be undertaken with appropriate clinical governance 
approval and protocols. 
 
More information in relation to ‘Issues in supervised consumption’ can be found at 
annexe A3 (Page 271) within the document.  
 
Buprenorphine products that dissolve more rapidly will be available and may require 
less supervision (More information relating to this can be found at section 4.3.4 ‘Faster 
acting forms of Buprenorphine (Page 89). 
 
Other medication such as benzodiazepines, antidepressants, antipsychotics and 
medication for conditions such as tuberculosis and Human Immunodeficiency Virus 
(HIV) can be prescribed to be dispensed in instalments and consumption supervised 
where local contracts are in place. The service should be delivered in a way that 
protects patients’ privacy and dignity. Consumption should take place in a private 
consultation room or a suitably discreet area of the pharmacy. There should also be 
due regard to maintaining confidential communication with patients in the open 
pharmacy area before and after any supervised use. 
 
While supervision of prescribed medication, even if directed on the prescription, is not 
a legal requirement, any deviation from the prescriber’s intended method of supply 
should be documented and the justification for this recorded. Any such decision should 
be made in the best interests of the patient, ideally always involving the prescriber. 
 
The third section to note under the Supervised Consumption Chapter is 4.5.4 




Staff supervising the consumption of medication need to be competent to do so. Such 
competencies are commonly specified in local service level agreements by 
commissioners. Standards that are required to deliver a quality OST supervised 
consumption service, and the training required by staff to deliver the service, are set 
out in the Scottish standards document, Pharmaceutical Care for Patients Prescribed 
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